Biomarkers and precision therapy for inflammatory diseases

Abstract

The present disclosure provides a biomarker for the accumulation of neutrophil extracellular traps (NETs) or extracellular chromatin. The present disclosure also provides methods for treating inflammatory diseases, including methods of predicting response to treatment, methods of selecting patients for treatment, and methods of determining therapeutic dosing.

Description

priority

[0001] This application claims the benefit and priority of U.S. Provisional Application No. 63 / 542,824, filed October 6, 2023, the contents of which are hereby incorporated by reference in their entirety.

[0002] Description of XML files submitted electronically This application contains a sequence list. The sequence list has been submitted electronically via EFS-Web as an XML file entitled “NTR-016PC_119601-5016_Sequence_Listing.xml”. The sequence list is 524,398 bytes in size and was created around October 6, 2024. The sequence list is hereby incorporated in its entirety by reference. Background Technology

[0003] Inflammatory and autoimmune diseases (including, but not limited to, systemic lupus erythematosus, or SLE) typically experience periods of relapse or “exacerbation” and intermittent periods of remission. By differentiating and / or predicting patients with active and inactive disease, patients with inflammatory diseases can be treated more effectively with pharmaceuticals and biologics. However, biomarkers are needed to differentiate subjects with active disease and / or monitor treatment to allow for more effective therapy. Attached Figure Description

[0004] Figure 1A and Figure 1B The results showed that the DNA enzyme 1-like 3 (D1L3) can rapidly and specifically depolymerize chromatin in nucleosomes and then further degrade DNA. Figure 1A A schematic diagram of chromatin substrates and nucleosome units is shown. Figure 1B The enzymatic activity of D1L3 on chromatin substrates was compared with that of DNase 1. As shown, DNase 1 digests chromatin to produce fragments of random sizes, indicating a lack of preferred sites for digestion. Furthermore, DNA remains even after 1 hour, suggesting that DNase 1 is inefficient in digesting chromatin. On the other hand, D1L3 digests chromatin to produce a ladder of fragments of varying sizes, consistent with digestion in the linker regions of nucleosomes, leading to the production of mononuclear and oligonuclear bodies, followed by efficient and complete digestion, as indicated by the near absence of DNA after 15 minutes of digestion.

[0005] Figures 2A to 2C This indicates that the D1L3 enzyme can produce circulating nucleosomes in the blood. Figure 2A A schematic diagram of the experiment is shown. Figure 2B This shows wild-type or... (The sentence is incomplete and requires more context to translate accurately.) DNA enzyme 1l3Dot plot of circulating DNA levels in knockout mice. Figure 2C The results of PCR-based determination of human Y chromosome DNA in wild-type mouse EDTA plasma samples obtained at baseline and 6 hours after injection of necrotic human male cells are shown. Figure 2D The wild-type (6 hours after injection of necrotic cells) is shown. Right now D1L3 + Results of agarose gel electrophoresis-based determination of DNA in mouse EDTA plasma samples. Fragment ladders of different sizes are consistent with D1L3 digestion, leading to the production of mononuclear bodies and oligonuclear bodies.

[0006] Figures 3A to 3C The identification of biomarkers for the accumulation of extracellular chromatin or extracellular traps in neutrophils is shown. Figure 3A The diagram shows a library of human genomic repetitive elements constructed using the Dfam database (left subgraph), and a schematic of a strategy for evaluating genomic repetitive elements as biomarkers. Figure 3B Two types of amplification products are shown. Type A is less than 150 base pairs and is resistant to DNase 1L3 fragmentation. Right now It is the final product of D1L3 activity. Type B is greater than 150 base pairs and is sensitive to D1L3 fragmentation. Right now It is a substrate and / or intermediate degradation product. Figure 3C This is a dot plot showing the percentage change in signal intensity of NET compared to completely degraded chromatin as a function of qPCR efficiency.

[0007] Figure 4A and Figure 4B This indicates that COVID-19 patients have a high NET burden in their tissues, which is alleviated by treatment with NTR-441 (SEQ ID NO: 137) (an engineered D1L3 drug candidate). Figure 4A This is a line graph showing the time progression of AluYm1 amplicon B (i.e., intermediate degradation products) levels in EDTA-treated plasma samples. Here, plasma represents the patient's blood circulation. The transient increase in AluYm1 amplicon B indicates intermediate degradation products of NET, which are produced by NTR-441-mediated NET digestion in tissues. These intermediate degradation products further degrade into mononuclear bodies, namely AluYm1 amplicon A. Figure 4B This is a dot plot showing the maximum level of AluYm1 amplicon type B (i.e., intermediate degradation product) in EDTA plasma samples.

[0008] Figure 5A and Figure 5BThis indicates that, prior to NTR-441 administration, a unique cytokine profile predicted the extent of repetitive element amplicon (e.g., AluYm1 amplicon type B) of supernucleosome length markers detectable in EDTA plasma samples derived from COVID-19 patients treated with NTR-441. Figure 5A This is a scatter plot of rho values ​​showing the Spearman correlation between pre-dose levels of 45 cytokines and the increase in AluYm1 amplicon B type in EDTA plasma samples after NTR-441 infusion, plotted as a function of probability values ​​(p-values). Figure 5B This is a scatter plot showing the maximum level of AluYm1 amplicon B type in EDTA plasma samples, plotted as a function of pre-dose IL-10 levels.

[0009] Figure 6A and Figure 6B This indicates that, following NTR-441 administration, a unique cytokine profile predicts the efficacy of NTR-441 in producing repetitive element amplicones (e.g., AluYm1 amplicon type B) that are supernucleosome length markers in EDTA plasma samples derived from COVID-19 patients. Figure 6A This is a line graph showing the time progression of serum G-CSF levels in patients who showed AluYm1 amplicon type B after NTR-441 treatment. Figure 6B The p-values ​​show the statistical significance of changes in G-CSF, IL-6, and CXCL10 levels at specified time points compared to baseline.

[0010] Figure 7A and Figure 7B This indicates that repeating element amplicones of supernucleosome length markers (e.g., AluYm1 amplicon type B) in serum samples predict the presence of neutrophil extracellular traps (NETs) in NET-related diseases. Here, coagulation activators in serum tubes induce blood cells to produce undigested or incompletely digested NETs, ​​which can be detected by AluYm1 amplicon type B. Figure 7A This is a dot plot showing the levels of AluYm1 amplicon type B in serum samples from controls, SLE patients, and COVID-19 patients. Figure 7B This is a dot plot showing the levels of AluYm1 amplicon 1 in serum samples from SLE patients in the clinically active and clinically inactive phases.

[0011] Figure 8A and Figure 8B This indicates that repeating element amplicones of supernucleosome length markers (e.g., AluYm1 amplicon type B versus AluYm1 amplicon type A) in serum samples from healthy subjects can help determine clinical dosage. Figure 8AThis is a line graph showing the concentration of AluYm1 amplicon B relative to AluYm1 amplicon A in the entire circulating DNA pool of serum collected from healthy subjects who received a single dose of NTR-441. Figure 8B This is a line graph showing the concentration of mononuclei in the entire circulating DNA pool in serum collected from healthy subjects who received a single dose of NTR-441.

[0012] Figures 9A to 9C It is illustrative. Figure 9A An illustrative lateral flow chamber is shown, which incorporates a cell separation pad to efficiently separate plasma from blood cells. Figure 9B An illustrative lateral flow test (LFT) is shown, which employs an ultra-bright gold nanoshell reporter gene (nanoComposix) to enhance sensitivity and visualize biomarkers on the test line without the need for instruments. Figure 9C The amplification and visualization of AluYm1 amplicon B using conventional PCR and detection on an AmpliDetect™ lateral flow cassette are shown. Detailed Implementation

[0013] In various aspects and embodiments, this disclosure provides a biomarker for inflammatory diseases to differentiate between subjects with active and inactive diseases, and to provide a precision therapy for patients with inflammatory diseases, including but not limited to systemic lupus erythematosus (SLE) and other autoimmune disorders. In embodiments, the biomarker is associated with neutrophil extracellular traps (NETs) and / or chromatin degradation products.

[0014] In various aspects and embodiments, this disclosure provides a method for detecting biomarkers of inflammatory diseases. The method includes determining the level of DNA fragments of genomic repetitive elements as described herein in a subject sample.

[0015] In various aspects and embodiments, this disclosure provides a method for treating an inflammatory disease in a subject. The method includes administering a treatment for the inflammatory disease, wherein the subject exhibits elevated levels of DNA fragments derived from repetitive DNA elements in a biological sample.

[0016] In various embodiments, the DNA fragment of the genomic repeat element is derived from AluYm1, which is a marker of NET and / or chromatin degradation products. In some embodiments, the DNA fragment of the genomic repeat element is greater than 150 base pairs (bp) and represents intermediate NET and / or chromatin degradation products. In some embodiments, the DNA fragment derived from AluYm1 is less than about 500 bp, or less than about 400 bp, or less than about 300 bp, or less than about 250 bp, or less than about 200 bp. In some embodiments, the DNA fragment derived from AluYm1 is greater than about 160 bp, or greater than about 180 bp, or greater than about 200 bp, or greater than about 225 bp, or greater than about 250 bp. In one embodiment, the DNA fragment derived from AluYm1 is about 200 bp.

[0017] In the implementation, the DNA fragment derived from AluYm1 comprises a nucleotide sequence represented by a nucleotide sequence selected from SEQ ID NO: 128-136, including its natural variants, which represent intermediate degradation products and are sometimes referred to herein as type B amplicon.

[0018] In some embodiments, the DNA fragment is amplified from a sample or detected after direct capture. In some embodiments, the DNA fragment is amplified by PCR. In some embodiments, the method uses forward and reverse primers selected from SEQ ID NO:7-127. In some embodiments, the forward primer has a nucleotide sequence selected from SEQ ID NO:38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, and 66. In some embodiments, the reverse primer has a nucleotide sequence selected from SEQ ID NO:37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, and 65. In an illustrative embodiment, the forward primer has the nucleotide sequence of SEQ ID NO:38, and the reverse primer has the nucleotide sequence of SEQ ID NO:39. In another illustrative embodiment, the forward primer has the nucleotide sequence of SEQ ID NO: 38, and the reverse primer has the nucleotide sequence of SEQ ID NO: 49.

[0019] In other embodiments, the DNA fragment is less than 150 base pairs and represents NET and / or chromatin completely degraded by the D1L3 enzyme. Such embodiments are sometimes referred to herein as type A amplicon. Illustrative type A amplicon has a nucleic acid sequence selected from SEQ ID NO: 128-354.

[0020] In some embodiments, the DNA fragment is amplified from a sample or detected after direct capture. In some embodiments, the DNA fragment is amplified by PCR. In some embodiments, the method uses forward and reverse primers selected from SEQ ID NO:7-127. In some embodiments, the forward primer has a nucleotide sequence selected from SEQ ID NO: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, and 126. In some embodiments, the reverse primer has a nucleotide sequence selected from SEQ ID NO: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, and 127. In some embodiments, the forward primer has a nucleotide sequence selected from SEQ ID NO: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, and 66. In some embodiments, the reverse primer has a nucleotide sequence selected from SEQ ID NO: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, and 65. In an illustrative embodiment, the forward primer has the nucleotide sequence of SEQ ID NO: 54, and the reverse primer has the nucleotide sequence of SEQ ID NO: 37. In an illustrative embodiment, the forward primer has the nucleotide sequence of SEQ ID NO: 54, and the reverse primer has the nucleotide sequence of SEQ ID NO: 39. In an illustrative embodiment, the forward primer has the nucleotide sequence of SEQ ID NO: 54, and the reverse primer has the nucleotide sequence of SEQ ID NO: 41. In the illustrative embodiment, the forward primer has the nucleotide sequence of SEQ ID NO: 54, and the reverse primer has the nucleotide sequence of SEQ ID NO: 43.

[0021] In the implementation plan, type A and type B amplicon were detected. Figure 3B ).

[0022] In some implementations, DNA fragments are quantified by qPCR. In one implementation, TAQMAN is used for qPCR. Generally, real-time polymerase chain reaction (qPCR) monitors the amplification of target DNA molecules during PCR (i.e., in real time). Real-time PCR can be used quantitatively and semi-quantitatively. Two common methods for detecting PCR products in real-time PCR are: (1) a non-specific fluorescent dye (e.g., SYBR Green (I or II)) inserted into any double-stranded DNA, and (2) a sequence-specific DNA probe (e.g., TAQMAN) labeled with a fluorescent reporter gene that allows detection only after the probe hybridizes to its complementary sequence.

[0023] In some implementations, the assay is TAQMAN real-time PCR. TAQMAN probes are hydrolytic probes designed to increase the specificity of quantitative PCR. The TAQMAN probe principle relies on the 5' to 3' exonuclease activity of Taq polymerase, utilizing fluorophore-based detection to cleave the double-labeled probe during hybridization with a complementary target sequence. The TAQMAN probe is double-labeled with a fluorophore and a quencher, and the fluorophore signal is detected when the fluorophore is cleaved from the oligonucleotide probe by Taq exonuclease activity (e.g., the signal is no longer quenched by the proximity of the label). As in other quantitative PCR methods, the resulting fluorescence signal allows for the quantitative measurement of product accumulation during the exponential phase of PCR. The TAQMAN probe architecture provides high sensitivity and specificity for detection.

[0024] In some embodiments, the DNA fragment is amplified by isothermal amplification. In some embodiments, isothermal amplification is recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), or single-primer isothermal amplification (SPIA). In some embodiments, isothermal amplification uses a forward primer having a nucleotide sequence selected from SEQ ID NO: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, and 66. In some embodiments, isothermal amplification uses a reverse primer having a nucleotide sequence selected from SEQ ID NO: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, and 65. In an illustrative embodiment, the forward primer has the nucleotide sequence of SEQ ID NO: 54, and the reverse primer has the nucleotide sequence of SEQ ID NO: 43. In the illustrative embodiment, the forward primer has the nucleotide sequence of SEQ ID NO: 54, and the reverse primer has the nucleotide sequence of SEQ ID NO: 41.

[0025] In embodiments, the DNA fragment is detected and / or quantified by a lateral flow assay. For example, the DNA fragment can be amplified using one or more primers conjugated to a detectable marker and a capture moiety. The LFA can be constructed from a nitrocellulose membrane and other components such as sample pads, conjugation pads, absorbent pads, or backing pads, as known in the art. Nitrocellulose membranes are widely used because they provide support for reaction and detection. Captured biomolecules (e.g., antibodies) are preferably deposited on the nitrocellulose via a combination of electrostatic interactions, hydrogen bonds, and / or hydrophobic interactions to form test lines and control lines.

[0026] In embodiments employing LFA, the DNA fragment is amplified using one or more primers conjugated to a detectable tag and a capture moiety. Non-limiting examples of nucleic acid tags that can be used include fluorescein (e.g., but not limited to fluorescein imide, fluorescein isothiocyanate (FITC), or carboxyfluorescein), digoxin, digoxigenin, Cy5, Texas Red, 2,4-dinitrophenyl (DNP), fluorescent molecules, quantum dot nanocrystals, semiconductor nanocrystals, upconversion phosphors, bioluminescent markers, luminescent oxygen channels, enzyme labels, paramagnetic particles, latex particles, etc.

[0027] In some embodiments, the reverse primer of each oligonucleotide pair is conjugated to a chemical or biochemical capture portion for diagnostic applications, wherein the capture portion is one member of a particular binding pair. In some embodiments, the other member of the particular binding pair is immobilized on a surface or other form of substrate to “capture” the amplification product containing the capture portion. Non-limiting examples of conjugable portions of the reverse primer include biotin or streptavidin, antibody / antigen pairs, etc.

[0028] In this implementation, elevated levels of the DNA fragment indicate an active inflammatory disease in the subject. In this implementation, the inflammatory disease is an autoimmune disease, such as systemic lupus erythematosus (SLE), and may involve lupus nephritis. In this implementation, the subject has one or both loss-of-function mutations in the DNase 1l3 gene. That is, the subject may have an inflammatory disease or an autoimmune disease (such as SLE), and measuring the level of the DNA fragment in a sample from the subject determines whether the subject has an active or inactive disease (e.g., remission). Patients with active disease may receive treatment to alleviate the disease, including potential exacerbations or relapses.

[0029] In this implementation, the subject suffers from an autoimmune disease selected from SLE, rheumatoid arthritis, multiple sclerosis, psoriasis, vasculitis, inflammatory bowel disease, and dermatomyositis. In this implementation, the subject suffers from gout or a coronavirus infection (e.g., SARS-CoV-2 or COVID-19). In this implementation, the subject suffers from or is at risk of thrombotic vascular disease, myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism, and sepsis. Other inflammatory diseases involving NETs are known in the art and are described in U.S. Patent No. 10,696,956, which is hereby incorporated by reference in its entirety.

[0030] SLE is a chronic, relapsing autoimmune disease affecting more than 5 million people worldwide, including 200,000 in the United States. Clinical manifestations of SLE include arthritis, rash, serositis, kidney disease, hematologic complications, and neuropsychiatric complications. Active SLE is characterized by widespread inflammation and deposition of antigen-antibody immune complexes in various organ systems. Antinuclear antibodies (ANA) and anti-double-stranded DNA antibodies (anti-dsDNA) are serological markers of SLE. ANA targets chromatin and its individual components, including double-stranded DNA (dsDNA), histones, and ribonucleoproteins. Active SLE is characterized by a response of T cells and B cells to nuclear antigens and the deposition of large amounts of antigen-antibody immune complexes in various organs and systems.

[0031] NETs play a crucial role in the pathogenesis of SLE and other autoimmune and inflammatory disorders, and are therefore therapeutic targets for patients with these conditions. A key characteristic of NETs is their intact DNA, which can exceed one hundred million base pairs in length, resulting in a reactive surface area thousands of times larger than that of the neutrophils from which they originate. Importantly, the DNA in NETs is organized in the form of chromatin, a large assembly of histones wrapped in double-stranded DNA (dsDNA). Each histone core is surrounded by approximately 150 base pairs of DNA. Each histone-DNA unit is called a nucleosome. The massive NET burden in inflammatory diseases, coupled with the inability to degrade and clear circulating multinucleosome DNA, leads to the formation of macroimmune complexes, triggering an inflammatory response and causing subsequent tissue damage.

[0032] Furthermore, loss-of-function mutations in DNase 1l3 can lead to familial forms of SLE, characterized by severe disease and early onset, highlighting the crucial role of DNase 1l3 in the disease. Therefore, in some embodiments, the subject has one or both loss-of-function mutations in the DNase 1l3 gene.

[0033] SLE is classified as mild, moderate, or severe. Mild SLE is defined as a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score <6, or a British Isles Lupus Assessment Group (BILAG) B score. Moderate SLE is defined as a SLEDAI-2K score between 6 and 10 and / or two or more BILAG B scores. Severe SLE is defined as a SLEDAI-2K score >10 and / or at least one BILAG A score. In the implementation plan, subjects have mild, moderate, or severe SLE.

[0034] Treatment of SLE typically involves long-term immunosuppression, which carries the risk of drug toxicity and impacts quality of life. Mild SLE is usually managed with NSAIDs, antimalarial drugs, and / or low-dose corticosteroids, while moderate SLE is treated with higher doses of corticosteroids and immunosuppressants. Severe SLE requires potent immunosuppressants, chemotherapy, and, in extreme cases, plasma exchange or cell therapy. Exemplary disease-modifying immunosuppressants used to treat SLE include azathioprine, mycophenolate mofetil, calcineurin inhibitors, and cyclophosphamide (for lupus nephritis (LN)). Biologics used to treat SLE include belimumab and anifrolumab. However, despite treatment, many patients continue to experience disease exacerbations and progression of varying severity. There are concerns that the existing diagnostic framework for SLE does not adequately capture the dynamic changes in the disease or specific organ involvement, which may influence treatment decisions.

[0035] Treatment of SLE typically involves long-term administration of a combination of different medications over many years. However, despite treatment, many patients continue to experience disease exacerbations of varying severity. D1L3 and engineered variants offer opportunities to improve therapies for SLE (as well as other rheumatic and inflammatory diseases, including gout and vasculitis), either by replacing existing therapies or in combination with them.

[0036] In the implementation, the sample is blood, serum, plasma, or urine. For example, a plasma sample represents the level of the target DNA fragment in the subject's blood circulation. Alternatively, the sample is serum. Processing a blood sample into serum can activate the production of NETs in the sample, thereby determining the level of NET formation in the subject.

[0037] In the implementation plan, subjects are tested approximately daily to approximately monthly to monitor their treatment. Alternatively, subjects may undergo testing once to 12 times per year, such as 2 to 8 times per year.

[0038] In various aspects and embodiments, a subject with elevated levels of DNA fragments is treated with a DNase (such as, but not limited to, parenteral DNase treatment). In some embodiments, the DNase is DNase 1, DNase 1-like 1, DNase 1-like 2, or DNase 1-like 3. In some embodiments, the DNase is DNase 1-like 3 (D1L3), and it is optionally fused directly or indirectly to a carrier protein via a linker, wherein said carrier protein is optionally albumin. Fusion with a carrier protein allows for enhanced pharmacokinetics. In some embodiments, the D1L3 enzyme has a complete or partial deletion of the C-terminal basic domain. See U.S. Patent Nos. 10,988,746; 11,840,712; and 11,578,314, which are hereby incorporated by reference in their entirety.

[0039] In some embodiments, the DNA enzyme therapy is the D1L3 enzyme described in WO 2024 / 107701, which is hereby incorporated herein by reference in its entirety. In some embodiments, the D1L3 enzyme comprises an amino acid sequence having at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 97% sequence identity with amino acids 21 to 282 of SEQ ID NO: 833 (isoform 1) or amino acids 21 to 252 of SEQ ID NO: 834 (isoform 2).

[0040] In some embodiments, the D1L3 enzyme comprises an N-terminal extension of at least four amino acids (e.g., 4 to about 18 amino acids). In some embodiments, the first N-terminal amino acid is neither a Met residue nor a Gly residue (which may undergo post-translational modification). In some embodiments, the last amino acid residue of the N-terminal extension is not a Ser residue, which may increase the immunogenicity risk of D1L3. In some embodiments, the last amino acid residue of the N-terminal extension is a Gly residue. In some embodiments, the N-terminal extension is predominantly Gly residues (i.e., more than 50% Gly residues). In some embodiments, the N-terminal extension comprises at least one cysteine ​​residue to provide site-specific chemical conjugation (such as with polyethylene glycol) or disulfide dimerization. In some embodiments, the N-terminal extension comprises or consists of the amino acid sequence SGGGG (SEQ ID NO: 835). In some embodiments, the N-terminal extension comprises or consists of the amino acid sequence CGGGG (SEQ ID NO: 836).

[0041] In some embodiments, the D1L3 variant further includes a C-terminal extension to reduce heterogeneity. In some embodiments, the C-terminal amino acid is lysine (Lys) or arginine (Arg). In some embodiments, the C-terminal extension comprises or is composed of an amino acid sequence SSR, which in some embodiments may be used for D1L3 variants that completely or partially lack the C-terminal basic domain. In yet other embodiments, D1L3 is encoded and expressed as having a 20-amino acid deletion with a basic domain, thereby having a sequence SSR at the C-terminus.

[0042] In some embodiments, the D1L3 variant comprises the deletion of at least three, at least five, at least eight, at least ten, at least twelve, at least fifteen, at least eighteen, at least twenty, or all 23 amino acids of the C-terminal basic domain (BD) defined by amino acids 283 to 305 of SEQ ID NO: 833. In some embodiments, the D1L3 variant comprises the deletion of 20 amino acids of the C-terminal basic domain (BD) defined by amino acids 283 to 305 of SEQ ID NO: 833, such that the D1L3 variant comprises a C-terminal extension of the sequence SSR.

[0043] In some embodiments, the D1L3 variants have a substitution of the amino acid corresponding to C48 of SEQ ID NO: 833. These variants can remove unpaired cysteine ​​residues, thereby improving the recombinant production and stability of the enzyme.

[0044] In some embodiments, this disclosure provides a D1L3 dimer according to this disclosure, optionally dimerized via a disulfide bridge at C48. In some embodiments, the D1L3 variant includes the introduction of a non-natural cysteine ​​residue that can promote dimerization, including the introduction of a non-natural cysteine ​​residue at the N-terminus. In such embodiments, this disclosure provides a D1L3 dimer that can be used in a therapy according to this disclosure. In some embodiments, the D1L3 variant includes a substitution of the cysteine ​​residue (C48) at position 48 of SEQ ID NO:833 to further control the dimerization position. For example, the mutation may be selected from C48A, C48G, and C48S. In some embodiments, the substitution of C48 (e.g., substitution to C48A or C48G) increases the enzymatic activity of the D1L3 enzyme (such as chromatin degradation). In some embodiments, the D1L3 variant has a C-terminal extension comprising an amino acid sequence SSR and a mutation at C48A (numbered in the absence of a signal peptide) of SEQ ID NO: 833, or consisting of the amino acid sequence and the mutation.

[0045] Exemplary D1L3 variants according to this disclosure include SEQ ID NO: 837, SEQ ID NO: 838, SEQ ID NO: 839, SEQ ID NO: 840, SEQ ID NO: 841, SEQ ID NO: 842 or SEQ ID NO: 843.

[0046] In some embodiments, the D1L3 variant comprises a fusion or conjugation with a half-life extension moiety. In some embodiments, the polymer is polyethylene glycol (PEG). In some embodiments, the PEG is conjugated to the N-terminus. In some embodiments, the PEG polymer links the D1L3 variant molecules via the N-terminus of two D1L3 variant molecules. In some embodiments, the PEG is conjugated to the C-terminus. In some embodiments, the PEG polymer links the D1L3 variant molecules via the C-terminus of two D1L3 variant molecules.

[0047] In some embodiments, treatment for inflammatory or autoimmune diseases includes (or further includes) the administration of immunosuppressive drugs. In some embodiments, the treatment includes one or more of corticosteroids, azathioprine, mycophenolate mofetil, cyclophosphamide, vorciclosporine, belimumab, and afluromab.

[0048] In embodiments, the level of DNA fragments is determined using EDTA plasma or serum, wherein the elevated level is an increase compared to a reference value. In embodiments, an EDTA plasma sample is obtained from the subject approximately 5 minutes to 48 hours after administration of the DNase therapy, optionally DNase 1-like 3 or a variant thereof as described. In such embodiments, this disclosure allows confirmation of binding of the DNase therapy to the target. In embodiments, one or more EDTA plasma samples are obtained at least approximately 15 minutes, or at least approximately 30 minutes, or at least approximately 1 hour, or at least approximately 2 hours, or at least approximately 3 hours, or at least approximately 4 hours, or at least approximately 6 hours, or at least approximately 8 hours, or at least approximately 12 hours, or at least approximately 18 hours, or at least approximately 24 hours, or at least approximately 36 hours, or at least approximately 48 hours after administration of the DNase therapy.

[0049] In one embodiment, the method further includes comparing the relative abundance of DNA fragments in EDTA plasma with baseline EDTA plasma obtained prior to administration of DNase therapy to confirm the therapeutic activity of the DNase therapy. In some embodiments, the abundance of DNA fragments in EDTA plasma is at least about 1.5 times greater, at least about 2 times greater, at least about 4 times greater, at least about 6 times greater, at least about 8 times greater, or at least about 10 times greater than baseline EDTA plasma, indicating that the DNase therapy targets the extracellular trap (ET) and / or neutrophil extracellular trap (NET).

[0050] In some embodiments, the sample is serum. In some embodiments, the serum is obtained before and / or after treatment (such as, but not limited to, the DNA enzyme therapy described above), and the abundance of DNA fragments allows for adjustment of the therapeutic dose. In embodiments, type A and type B amplicones are detected and / or quantified to analyze intermediate and complete NETs and / or chromatin degradation products present in the serum sample. In embodiments, the method further includes comparing the relative abundance of DNA fragments in the serum with one or more reference values ​​or baseline values. In embodiments, the reference values ​​represent the relative abundance of DNA fragments in serum during the active state of the inflammatory disease and / or the inactive state of said inflammatory disease.

[0051] In some implementations, the abundance of DNA fragments in serum is at least about 1.5 times greater, at least about 2 times greater, at least about 4 times greater, at least about 6 times greater, at least about 8 times greater, or at least about 10 times greater than one or more reference values, indicating that DNA enzyme therapy targets the extracellular trap (ET) and / or the neutrophil extracellular trap (NET).

[0052] In some implementations, a reduction in the abundance of DNA fragments by at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90% relative to baseline indicates appropriate dosage.

[0053] In some embodiments, the method includes or further includes measuring the amount or activity of IL-10 and / or VEGF-A in a biological sample obtained from a subject. In some embodiments, if the biological sample has elevated IL-10 and / or lower VEGF-A compared to one or more reference values, the method includes administering a DNAse 1-like 3 enzyme or a derivative thereof to the subject.

[0054] In some embodiments, the biological sample is selected from blood, plasma, serum, or urine. In some embodiments, the amount or activity of IL-10 and / or VEGF-A is measured by contacting the sample with one or more agents that specifically bind to the amount or activity of IL-10 and / or VEGF-A. In some embodiments, one or more agents that specifically bind to the amount or activity of IL-10 and / or VEGF-A are antibodies or fragments thereof.

[0055] In some embodiments, the method includes or further includes measuring the amount or activity of G-CSF, IL-6, and / or CXCL10 in a post-dose biological sample obtained from a subject who has been administered DNase 1-like 3 enzyme or a derivative thereof. In some embodiments, if the amount or activity of G-CSF, IL-6, and / or CXCL10 in the post-dose biological sample is low compared to one or more reference values, the method includes continuing therapy with DNase 1-like 3 or a variant thereof.

[0056] In some embodiments, the biological sample is selected from blood, plasma, serum, or urine. In some embodiments, the amount or activity of IL-10 and / or VEGF-A is measured by contacting the sample with one or more agents that specifically bind to or are active to G-CSF, IL-6, and / or CXCL10. In some embodiments, one or more agents that specifically bind to or are active to G-CSF, IL-6, and / or CXCL10 are antibodies or fragments thereof.

[0057] In one aspect, this disclosure further provides kits for detecting and / or amplifying DNA fragments derived from repetitive DNA elements. The kits include forward and reverse primers as described herein, and optionally one or more detection reagents. For example, but not limited to, the kits may include one or more of the following components: (i) at least one reaction chamber for performing polymerase amplification reactions; and / or (ii) at least one nucleic acid lateral flow assay device; and / or (iii) at least one sample collection device.

[0058] Any reaction chamber known in the art for amplification reactions (such as, but not limited to, RPA and PCR) may be utilized according to this disclosure. The reaction chamber may contain one or more dried reagents for performing the amplification reaction. For example (but not limited to), when the reaction is an RPA reaction, the reaction chamber may contain a dried reagent composition comprising a recombinase, a polymerase, and a single-stranded DNA-binding protein. Non-limiting examples of reaction chambers that may be used according to this disclosure include those disclosed in US 10,036,057 and 10,538,760, the contents of which are hereby expressly incorporated herein by reference in their entirety.

[0059] Any nucleic acid lateral flow assay device known in the art for detecting amplification products can be utilized according to this disclosure. Such devices are well known in the art and are commercially available; two non-limiting examples include the MileniaHybriDetect lateral flow test strip (Milenia Biotec GmbH, GieBen, Germany) and the PCRD Nucleic Acid Lateral Flow Immunoassay (NALFIA) kit (Abingdon Health, York, UK). Further non-limiting examples of nucleic acid lateral flow assay devices used in combination with RPA reaction chambers are disclosed in U.S. Patent Nos. 10,036,057 and 10,538,760, the contents of which are hereby expressly incorporated herein by reference in their entirety.

[0060] As used herein, unless the context otherwise requires, the term “about” means a value of ±10% of the reference value.

[0061] Various aspects and implementations of this disclosure will become apparent from the following non-limiting examples.

[0062] Example Example 1: Characterization of chromatin degradation activity of DNase 1-like 3 (D1L3) in vitro Using high molecular weight (HMW) chromatin ( Figure 1A For example, purified nuclei from HEK293 cells were used to compare the DNase activity of D1L3 on chromatin substrates with that of DNase 1. In short, HMW chromatin was first incubated with DNase, followed by DNA isolation and visualization via agarose gel electrophoresis (AGE). Figure 1B As shown, D1L3 digests chromatin within seconds to produce a ladder of fragments of varying sizes, consistent with the digestion of the nucleosome adapter regions, leaving behind primarily mononucleosomes and some oligonucleosomes. The DNA from the mononucleosomes and oligonucleosomes is then completely degraded in less than 15 minutes. Figure 1B On the other hand, DNase 1 is not efficient at digesting chromatin; DNA remains even one hour after the digestion reaction. Figure 1B In addition, DNase 1 produced a stripe of degraded DNA without a distinct structure. Figure 1B These results indicate that DNAse 1 lacks a preferred digestion site.

[0063] These results indicate that the D1L3 enzyme rapidly and specifically depolymerizes chromatin in nucleosomes and then further degrades DNA.

[0064] Example 2: Characterization of the chromatin degradation activity of D1L3 in vitro DNase 1-like 3 (D1L3) is secreted into the bloodstream by immune cells. It is the main DNA-degrading enzyme in the blood. DNase 1 is the main DNase in urine. D1L3 plays a major role in shaping the DNA fragmentation pattern in plasma-free cells. Zhou et al. , Fragmentation landscape of cell-free DNA revealed by deconvolutional Analysis of end motifs , Proc. Natl. Acad. Sci. USA 120 (17) e2220982120. Serum DNase activity on chromatin substrates was characterized by injection (intraperitoneal) of necrotic human male cells into wild-type female mice compared to mice with DNase 1l3 knockout. Figure 2A ).

[0065] EDTA plasma was prepared from blood extracted from mice that received necrotic human male cells, and total circulating DNA was quantified at baseline and 6 hours after injection of necrotic cells. Figure 2B As shown, wild-type mice exhibited significant amounts of circulating DNA in their plasma 6 hours after injection of necrotic cells, but not at baseline, indicating that the observed circulating DNA was formed by necrotic cells. In contrast, DNase 1l3 knockout mice showed only background levels of total circulating DNA at both baseline and 6 hours after injection of necrotic cells. Figure 2B ). with DNAse 1L3 - / - Compared to wild-type mice, the amount of total circulating DNA was significantly higher in wild-type mice (p<0.0001). Figure 2B These results indicate that plasma D1L3 digests the chromatin of necrotic cells, thereby producing circulating DNA.

[0066] To confirm that the observed circulating DNA originated from necrotic cells, human Y chromosome-specific markers were amplified using polymerase chain reaction (PCR). Figure 2C As shown, human Y chromosome DNA was amplified from wild-type mouse plasma samples obtained 6 hours after injection of necrotic cells, but not at baseline. These results indicate that circulating DNA originates from necrotic human male cells. Circulating DNA from wild-type mice was resolved and visualized using agarose gel electrophoresis. Figure 2D As shown, circulating DNA forms a ladder of fragments of varying sizes, consistent with the fact that DNA primarily originates from mononuclear bodies and some oligonuclear bodies. This digestion pattern is consistent with D1L3 digestion of chromatin. Figure 1B ).

[0067] Example 3: Development of biomarkers for the accumulation of extracellular chromatin or extracellular trapping nets (NETs) in neutrophils Experiments were conducted to identify nucleosome-based biomarkers enriched under conditions of NET or extracellular chromatin accumulation. In short, the Dfam database is used to assemble libraries of repetitive elements from the human genome. Figure 3ATarget elements included transposable elements, including long interpenetrating nuclear elements (LINEs) and short interpenetrating nuclear elements (SINEs). A total of 91 target sequences were scored based on their length and frequency in the human genome. DNA sequences shorter than 150 base pairs were excluded from further development because approximately 147 bp of DNA is encased around a mononuclear body.

[0068] To obtain nucleosome-based biomarkers, the following target sequences were evaluated: AluSp (DF0000042.4), AluYh3 (DF0001318.2), AluYm1 (DF0001154.2), AluYa5 (DF0000053.4), AluSq (DF0000043.4), AluSq2 (DF0000045.4), AluYk2 (DF0001169.2), AluJo (DF0000034.4), AluJr (DF0000035.4), AluSz (DF0000051.4), AluSx1 (DF0000048.4), AluJb (DF0000007.4), AluSz6 (DF0000052.4), AluSx (DF0000047.4), AluJr4 (DF0000036.4), AluYk4 (DF0000066.4), AluSq10 (DF0000044.4), AluYg6 (DF0000634.4), AluYb9 (DF0000056.4), AluYb8 (DF0000055.4), AluYk12 (DF0000065.4), AluYk11 (DF0000064.4), AluYj4 (DF0001320.2), AluY (DF0000002.4), AluYi6_(DF0001316.2), AluSc8 (DF0000038.4), AluYi6 (DF0001197.2), AluYf1 (DF0001317.2), AluYk3 (DF0001145.2), AluYh7 (DF0001321.2), AluYh9 (DF0000063.4), AluSq4 (DF0000046.4), AluSx3 (DF0000049.4), AluYe5 (DF0001240.2), AluSg4 (DF0000040.4), AluYe6 (DF0001174.2), AluYa8 (DF0000054.4), AluSg (DF0000039.4), AluSx4 (DF0000050.4), AluSc (DF0000003.4), AluSc5 (DF0000037.4), AluSg7 (DF0000041.4), AluYc3 (DF0000058.4), AluYd8 (DF0000060.4), AluYc (DF0000057.4), L1M1_(DF0000227.4), L1M1 (DF0000228.4), L1P4_(DF0000326.4), L1PB_(DF0000354.4), L1P3_(DF0000320.4), L1P1 _(DF0000316.4), L1PA12_(DF0000778.4), L1PBa_(DF0000352.4), L1PA15-16 (DF0000334.4), L1PA13_(DF0000332.4), L1PA14_(DF0000773.4), L1P4a_(DF0000321.4), L1PA10_(DF0000 328.4), L1P1_(DF0000315.4), L1HS_(DF0000226.4), L1P4d_(DF0000324.4), L1P4b_(DF0000322.4), L1PA17 _(DF0000338.4), L1P3_(DF0000318.4), L1PBa1_(DF0000351.4), 1P4c_(DF0000323.5), L1P4e_(DF0000325. 4), L1P3b_(DF0000319.4), L1PBb_(DF0000353.4), L1MA3_(DF0000258.5), L1MA2_(DF0000257.4), L1MA1_(D F0000256.4), L1PA11_(DF0000329.4), L1PA8_(DF0000345.4), L1PA10_(DF0000327.4), L1PA12_(DF0000330 .4), L1PA17_(DF0000337.4), L1PA16_(DF0000336.4), L1PA15_(DF0000335.4), L1PA13_(DF0000331.4), L1P The following are product codes: A14_(DF0000333.4), L1PA4_(DF0000341.4), L1PA3_(DF0000340.4), L1PA2_(DF0000339.4), L1HS_(DF0000225.4), L1PB3_(DF0000349.4), L1PA7_(DF0000344.4), L1PA5_(DF0000342.4), L1PB2_(DF0000348.4), L1PB1 (DF0000347.4), and L1PA8A_(DF0000346.4).

[0069] Seventeen sequences were selected, with the top-ranked sequences including LINE-1 family members (L1M1, L1P4, L1PB) and ALU family members (AluSp, AluYh3, AluYm1) with lengths >310 base pairs. The illustrative target common sequences are SEQ ID NO: 1-6. Interchangeable forward and reverse primer libraries were designed and combined in matrix form to generate a screening library of potential diagnostic assays, which vary by targeting different positions and / or variable amplicon lengths. The illustrative primers are SEQ ID NO: 7-127.

[0070] As shown in Example 2, necrotic cells or their chromatin and NETs remain in the tissue. Therefore, they are not easily detected in plasma or serum. Thus, both nucleosomes (the final product of D1L3 activity) and intermediates of NET degradation (such as oligonucleosomes) can be easily detected in plasma or serum. Figure 3B Two types of illustrative amplification products are shown. Type A is less than 150 base pairs and is resistant to DNase 1L3 fragmentation. Right now It is the final product of D1L3 activity. Type B is greater than 150 base pairs and is sensitive to D1L3 fragmentation. Right now It is a substrate and / or intermediate degradation product.

[0071] Following initial evaluation using clinical serum samples (collected for the NTR-441 assay) from healthy subjects, a primer pair designated AluYm1 amplicon 1 was selected, amplified by SEQ ID NO 128-136. Serum is generated by allowing blood to clot, optionally by exposing blood to an activated surface (e.g., silica). Clotting leads to the activation of clotting factors, platelets, and neutrophils, resulting in the production of NETs. Therefore, unlike plasma, serum is rich in undigested DNA fragments from the NETs produced during blood clotting. As disclosed herein, serum can be used to determine an effective dose of DNase therapy during Phase 1 studies in healthy subjects, and also in later clinical development in patients. Figure 3C This is a dot plot showing the percentage change in signal intensity of NET compared to completely degraded chromatin as a function of qPCR efficiency. AluYm1 amplicon counts were significantly reduced 15 minutes and 4 hours after initiation of NTR-441 compared to pre-dose levels. NTR-441 is an engineered D1L3 enzyme whose N-terminus is fused to albumin via a Gly-Ser linker.

[0072] Example 4: Demonstration of target binding in NTR-441 treatment of patients with high NET burden NTR-441 is an albumin-D1L3 variant fusion protein. A randomized, placebo-controlled, double-blind, phase 1 study was conducted to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of NTR-441 administered via intravenous infusion in healthy adults and COVID-19 patients hospitalized for COVID-19 pneumonia.

[0073] Pre-dose blood samples from healthy adults and COVID-19 patients hospitalized for COVID-19 pneumonia were collected in EDTA plasma tubes and administered NTR-441 or placebo via intravenous infusion. Blood samples were collected in EDTA plasma tubes at 4, 8, 12, 24, and 48 hours post-administration. Plasma samples were prepared, and the presence of AluYm1 amplicon 1 was determined using a quantitative PCR-based assay. Figure 4A As shown, compared with pre-dose samples, the level of AluYm1 amplicon 1 was elevated in patients who received NTR-441 at 4, 8, or 24 hours post-dose, depending on the patient (this may be due to differences in the ability of NTR-441 to enter the NET). No dose-dependent effect of NTR-441 was detected, which is consistent with the lowest dose observed in ex vivo assays. Right now NTR-441 (0.3 mg / kg) showed effective target binding consistency. In each patient exhibiting elevated AluYm1 amplicon 1 levels, subsequent samples showed a decrease in AluYm1 amplicon 1 to background levels. Figure 4A Patients treated with placebo did not show such an increase (or decrease) within 48 hours. Figure 4A Of the nine COVID-19 patients who received NTR-441 infusions, eight patients showed peak AluYm1 amplicon 1 levels within 48 hours, but no peak was observed in COVID-19 patients who received placebo. Figure 4A Following NTR-441 infusion in healthy subjects, no peak was observed in AluYm1 amplicon 1 levels, confirming the drug target (…). Right now The fact that NETs and necrotic cell nuclei were not exposed in healthy subjects. Figure 4B This is a dot plot showing the maximum level of AluYm1 amplicon 1 in EDTA plasma samples. (See image.) Figure 4B As shown, the maximum plasma concentration of AluYm1 amplicon 1 was significantly higher in patients treated with placebo (p<0.0182).

[0074] These results indicate that NETs and other extracellular chromatin are present in patient tissues (e.g., lungs). As discussed above, since the length of the supernucleosome length marker exceeds 150 bp, which surpasses the length of DNA in mononucleosomes, the detected amplicon represents chromatin / NETs in plasma that were not fully digested due to the activity of NTR-441. Therefore, these results indicate a transient increase in intermediate degradation products of NETs in the bloodstream after administration of NTR-441 to COVID-19 patients, confirming target binding. A decrease in NETs to background levels indicates that NTR-441 completely degraded oligonucleosome or mononucleosome DNA.

[0075] Example 5: Predicting the target of NTR-441 in COVID-19 subjects by pre-administration cytokine profiling Standard joint Panels measuring 45 cytokines were collected from plasma samples of COVID-19 patients immediately prior to NTR-441 infusion. Pre-dose cytokine levels correlated with the extent of target binding and processing, defined as an increase in AluYm1 amplicon 1 following NTR-441 infusion. Figure 5A This is a scatter plot of the Spearman correlation (rho values) between pre-dose levels of 45 cytokines and the increase in AluYm1 amplicon 1 in EDTA plasma samples after NTR-441 infusion, plotted as a function of probability values ​​(p-values). Interleukin-10 (IL-10) levels were strongly positively correlated with AluYm1 amplicon 1 (Spilman rho = 0.833, p = 0.005). Figure 5A Vascular endothelial growth factor A (VEGF-A) levels were negatively correlated with AluYm1 amplicon 1 (Spearman rho = -0.833, p = 0.005). Figure 5A ).

[0076] These results indicate a unique cytokine profile (IL-10) prior to NTR-441 administration. 高 and / or VEGF-A 低 This predicts the degree of target binding in COVID-19 patients. These results suggest that the observed cytokine profile can be used to select patients for NTR-441 treatment.

[0077] Example 6: Prediction of NTR-441 target binding based on cytokine profiles after NTR-441 administration Panels measuring 45 cytokines were collected from plasma samples of COVID-19 patients immediately before and at various time points after NTR-441 infusion. Changes in cytokine profiles were analyzed in two groups. The first group included COVID-19 patients who received NTR-441 infusion and showed the highest levels of AluYm1 amplicon 1. The second group included all eight other COVID-19 patients, including three who received placebo.

[0078] like Figure 6A As shown, among 45 cytokines, G-CSF exhibited the most significant changes. In patients with high AluYm1 amplicon 1 levels, levels rapidly decreased within 4 hours following NTR-441 infusion. G-CSF levels returned to normal within 24 hours and remained low for the remainder of the study duration. Figure 6A Other cytokines also showed significant reductions compared to pre-dose levels, including IL-6 and CXCL10. Figure 6B ).

[0079] NET contains a neutrophil serine protease with enzymatic activity that degrades cytokines. Furthermore, neutrophil elastase specifically degrades G-CSF and antagonizes its role in granulocyte production. Therefore, these results suggest that target binding and clearance of NTR-441 in COVID-19 patients triggers a potential negative feedback loop in granulocyte production.

[0080] These results further indicate that a unique cytokine profile with reduced G-CSF, IL-6, and / or CXCL10 levels after NTR-441 administration predicted the extent of target binding and clearance in COVID-19 patients. These results suggest that the observed cytokine profile can be used to select patients suitable for NTR-441 treatment or to select NTR-441 suitable for patients requiring treatment.

[0081] Example 7: Serum NET biomarker levels predict extracellular neutrophil levels in NET-related diseases The existence of trap nets Serum is produced by allowing blood to clot, optionally by exposing blood to an activated surface (e.g., silica). Clotting leads to the activation of clotting factors, platelets, and neutrophils, resulting in the production of NETs. Therefore, unlike plasma, serum is rich in undigested DNA fragments from NETs produced during blood clotting. The amount of AluYm1 amplicon B type in serum samples from patients with NET-related diseases was investigated. For this purpose, serum from COVID-19 patients or SLE patients was compared with serum from controls. Figure 7A This is a dot plot showing the levels of AluYm1 amplicon type B in serum samples from controls, SLE patients, and COVID-19 patients. Figure 7A As shown, serum samples from SLE patients (p<0.0001) and COVID-19 patients (p = 0.0576) showed a significant increase in AluYm1 amplicon type B compared to control samples.

[0082] Serum from SLE patients in the clinically active phase was compared with serum from SLE patients in the clinically inactive phase. Figure 7BThis is a dot plot showing the levels of AluYm1 amplicon 1 in serum samples from SLE patients in the clinically active or inactive phase. Figure 7B As shown, compared with control samples, serum from SLE patients in the clinically active phase showed a significant increase in AluYm1 amplicon 1 (p<0.007) compared with serum from SLE patients in the clinically inactive phase.

[0083] These results indicate that serum AluYm1 amplicon 1 concentrations reflect the extent of NETosis occurring in neutrophils upon activation (e.g., during blood clotting), and this extent is increased in patients with clinical symptoms of SLE compared to healthy controls. SLE patients without clinical symptoms but with elevated serum AluYm1 amplicon 1 levels may be at risk of developing lupus exacerbations.

[0084] Blood samples were taken from stroke patients undergoing thrombectomy, including those who received tPA prior to the procedure. Serum from stroke patients was compared with serum from controls to determine the level of AluYm1 amplicon 1. An increase in AluYm1 amplicon 1 was expected from the serum from stroke patients compared with the control sample.

[0085] Example 8: Detection of NET biomarkers in serum to predict effective dose Pre-dose blood samples from healthy adults were collected in serum tubes, and they were administered single doses of NTR-441 at different doses. Post-dose blood samples were collected in serum tubes. Serum was prepared, and AluYm1 amplicon 1 in all samples was quantified. The relative levels of serum AluYm1 amplicon 1 were plotted as a function of NTR-441 dose. Serum AluYm1 amplicon 1 (a DNA fragment larger than a mononuclear body) reflects the degree of neutrophil NETosis. Figure 8A As shown, after receiving a single dose of NTR-441, the concentration of AluYm1 amplicon B in all circulating DNA pools in serum collected from healthy subjects (detected by AluYm1 amplicon A) decreased in a dose-dependent manner.

[0086] These results indicate that the detection of NET biomarkers in serum samples can be used to determine the effective dose of DNA enzyme therapy during Phase 1 studies in healthy subjects, and also to determine the effective dose in later clinical development in patients.

[0087] Example 9: Further Development for the Determination of NET Biomarkers According to this disclosure, the disease specificity of the AluYm1 amplicon and its stability during active disease were determined, as well as the threshold for positive precision biomarker testing of the AluYm1 amplicon in patients with active SLE. These studies identified target populations of SLE patients who would benefit from D1L3 therapy in some embodiments.

[0088] To develop the AluYm1 amplicon as a precision biomarker, this disclosure provides three desirable performance parameters: (1) a threshold for determining a positive precision biomarker test for the AluYm1 amplicon; (2) the stability of a positive AluYm1 amplicon test during active SLE measured over time; and (3) the specificity of a positive biomarker test for SLE and other rheumatoid diseases.

[0089] To determine the threshold for a positive AluYm1 amplicon test, data will be collected using a validated procedure with specifications for inter-operator, intra-operator, and operator-dependent assay variability conforming to Good Clinical Laboratory Practice (GCLP) standards. The assay will first be validated as a qPCR protocol for AluYm1 amplicon. Interim analyses will be performed on serum and plasma samples from 100 SLE patients using the validated method. The threshold for a positive test will be determined based on the mean concentration of AluYm1 amplicon in inactive / remission SLE patients, defined according to the protocol as a sum of SLEDAI-2K clinical descriptive scores below 6. Preliminary data on AluYm1 amplicon from 12 patients will be used to calculate a sample size sufficient to identify a cutoff value distinguishing between active and inactive SLE. A sample size of 21 per group would have 90% capability to detect a difference in means of -96.635 (the difference between mean μ1 of group 1, which is 23.615, and mean μ2 of group 2, which is 120.25), assuming a two-group t-test with a two-sided significance level of 5% and a common standard deviation of 92.03. This exploratory statistical analysis ensures that the study will have the necessary statistical power to detect meaningful differences between groups and provide reliable results to produce robust cutoff values ​​to distinguish between the two groups. Considering additional covariates (such as age, sex, disease activity, and laboratory parameters of SLE disease), a larger sample size is needed to increase the robustness of the threshold determination, control its effects, and assess the relationship between the biomarker and SLEDAI-2K. The smaller sample size required for the AluYm1 amplicon suggests that it may be a more sensitive biomarker than cell-free DNA in distinguishing between two groups of active and inactive SLE to detect differences in means. This potential sensitivity could indicate a stronger and more pronounced association between the AluYm1 amplicon and SLE disease activity.

[0090] To achieve the second objective, AluYm1 amplicon levels in individual patients will be compared at initial and follow-up visits. The time between visits is estimated to be approximately 1 to 12 weeks. This approach will determine whether the increase in AluYm1 amplicon levels in SLE patients during active disease is permanent or transient. A secondary objective is to determine whether the increase in AluYm1 amplicon is specific to active SLE. Given observations of circulating DNA in patients with rheumatic diseases, AluYm1 amplicon levels are expected to be elevated in indications other than SLE. To demonstrate this experimentally, observational studies could enroll patients with rheumatoid arthritis, gout, and vasculitis during active disease and remission. Considering consistent biomarker variability and factors of disease prevalence and heterogeneity, the study would involve a total sample size of 200 patients with rheumatoid arthritis, 100 patients with gout, and 20 patients with vasculitis, with the aim of differentiating between active and inactive disease states. If a selective increase in AluYm1 amplicon is detected during active disease, this approach will allow precision medicine to be extended to other rheumatic diseases.

[0091] AluYm1 amplicon assays will be used to differentiate between patients with active SLE (clinical SLEDAI-2K score ≥6) and inactive SLE (clinical SLEDAI-2K score <6). Optionally, healthy (non-SLE) subjects may be used instead of inactive patients. To analyze the changes and stability of biomarkers over time, repeated measures ANOVA or linear mixed-effects models will be employed, specifically designed to assess multiple measures data from the same subject at different time points. Statistical analyses will be able to identify significant differences in biomarker means over time, providing insights into their trends and overall stability. These studies will provide a binary classifier (positive / negative) and establish inclusion criteria for SLE patients during interventional trials of DNase 1L3 therapy, and will provide pharmacodynamic endpoints.

[0092] Characterization of AluYm1 amplicon stability will determine clinical development strategies for precision therapies for SLE. Temporary increases in AluYm1 amplicon levels during active SLE require close monitoring during clinical development (e.g., point-of-care testing), while stable increases in AluYm1 amplicon levels during active SLE allow for testing of blood samples in a central laboratory.

[0093] This disclosure further provides an optimized qPCR-based AluYm1 amplicon assay for use as a point-of-care test. The initial procedure for measuring AluYm1 amplicones can take up to five days, from collecting blood from a patient with active SLE to the treating physician receiving test results and the patient's potential initiation of targeted therapy. During this time, the blood is processed, frozen, and transported to a laboratory with dry ice, where DNA is isolated from the blood sample (plasma / serum) and AluYm1 amplicones are analyzed by qPCR. Based on these follow-up studies, the time between blood sampling and receiving test results has been shortened. This could be important for effective therapy, as timely initiation of therapy reduces the extent of organ damage caused by NETs. Furthermore, if AluYm1 amplicon levels are only temporarily elevated during active SLE, point-of-care testing for precision therapy is required.

[0094] For example, the PCR equipment will be optimized using a mobile qPCR device and an assay protocol capable of being performed at the point of care (e.g., clinics, clinical trial sites, and mobile laboratories). In the implementation, the mobile qPCR device weighs less than 5 pounds, while a typical benchtop qPCR device weighs >150 pounds. By transferring the qPCR protocol to the mobile device and then optimizing the assay efficiency, the extent of target DNA amplification in each PCR reaction cycle can be determined. For reactions containing standard purified human genomic DNA (Promega, catalog number G3041) at known concentrations, efficiencies will be calculated individually over a 7-log concentration range. In preliminary studies, the AluYm1 amplicon mobile qPCR assay showed good linearity over a wide concentration range, with assay efficiencies in the 80–90% range. Computational analysis of the AluYm1 amplicon predicted GC content, melting temperature, and primer dimerization tendency favorable to qPCR. The specificity of AluYm1 amplicon-mediated amplification was assessed by agarose gel electrophoresis, observing a single band of the expected size, approximately 200 bp. Additional parameters affecting assay efficiency will be optimized, such as primer concentration, different commercial sources of qPCR reaction components, reaction conditions (annealing temperature, extension time, cycling parameters), DNA extraction methods, purification steps, and storage conditions. Once assay efficiency is optimized for mobile qPCR devices, the limit of detection (LOD) and reproducibility will be characterized.

[0095] In some implementations, a direct qPCR method for AluYm1 amplicon can be performed directly on patient samples (e.g., serum, plasma, urine, and other samples such as tears, cerebrospinal fluid, and bronchoalveolar lavage fluid) without DNA isolation. For example, the direct qPCR method may involve diluting the sample and adjusting standard qPCR assay parameters. Master mixes specifically designed for direct qPCR applications are commercially available.

[0096] In some aspects and implementations, this disclosure provides a prototype of a lateral flow assay (LFT) for home testing of the AluYm1 amplicon. LFTs have been used in the diagnostics field for decades due to their accuracy, rapid readouts, and ease of home use. Most LFTs employ antibody-specific binding to a target analyte from a matrix (such as blood, urine, nasal secretions, etc.), complexing it with a visualized macromolecule or particle (e.g., gold nanoparticles), and capturing and concentrating the complex on a discrete region on the test strip, thereby achieving a visualized readout (i.e., the test line). In addition to well-known commercial LFTs (e.g., home pregnancy and drug testing, virus testing), a large body of literature describes the utility of LFTs in detecting nucleic acids in complex matrices.

[0097] In some implementations, the AluYm1 amplicon LFT uses venous blood, capillary blood, or urine. In some implementations, the LFT sample is capillary blood. A suitable lateral flow cassette combined with a cell separation pad enables efficient separation of plasma from blood cells. Figure 9A In various implementations, LFT involves the direct capture of AluYm1 amplicon 1 from patient samples, i.e., without an amplification step. Alternatively, biomarker capture may follow isothermal amplification. Direct capture of target nucleic acids from blood followed by lateral flow elucidation has been demonstrated for microRNAs. For example, direct capture can be achieved using specialized peptide nucleic acids (PNAs) having an uncharged backbone of N-(2-aminoethyl)-glycine units linked by peptide bonds. This chemical property of PNAs facilitates strand invasion of double-stranded nucleic acids via complementary sequence base pairing, with binding affinity far exceeding that of standard DNA or RNA duplexes. In some implementations, LFT may employ ultrabright gold nanoshell reporter genes (nanoComposix) to enhance sensitivity and visualize biomarkers on a test line without the need for instruments. Figure 9B The AluYm1 amplicon sequence will be used to design two PNA probes: (1) a 6-carboxyfluorescein (6FAM)-labeled PNA capture probe (using the AluYm1 amplicon forward primer sequence) to functionalize the anti-FAM coated gold nanoshell and bind to the target sequence; and (2) a biotin-labeled PNA sensing probe (using the AluYm1 amplicon reverse primer sequence) to concentrate the gold nanoshell complex on the test line. Synthetic double-stranded DNA with complete common sequences for AluYm1 amplicon primer design has been generated to serve as a standard for testing the PNA-based LFT. Initial experiments will be performed using this standard in physiological buffers containing and excluding macromolecular crowding reagents known to enhance lateral flow assays. Purified genomic DNA will be used as a standard to determine the visual detection limit (LOD) of the biomarker.

[0098] If direct PNA-based methods are not sensitive enough or do not ideally visualize AluYm1 amplicons in human samples, an AluYm1 amplicon amplification step can be added. Amplification can be performed using conventional PCR or isothermal amplification. In preliminary studies, AluYm1 amplicons were amplified and visualized using conventional PCR on an AmpliDetect™ lateral flow chamber. Figure 9C In short, 6FAM-labeled and biotin-labeled AluYm1 amplicon forward and reverse primers were used, with Promega's GoTaq™ Master Mix and human genomic DNA as templates. The completed PCR reaction solution was diluted and mixed with nanoComposix anti-FAM functionalized gold nanoshells and applied to an AmpliDetect™ lateral flow cassette. We observed significant test lines when the PCR reaction solution was diluted to 1:100, indicating efficient incorporation of the labeled AluYm1 amplicon primers into the amplicon. This provides strong proof of principle that AluYm1 amplicons can be amplified using chemically end-labeled primers, and that labeled AluYm1 amplicon amplification products can be visualized using only commercially available lateral flow test strips, without the need for any specialized instruments.

[0099] Because the aforementioned amplification step requires a thermal cycler, and one goal is to provide point-of-care or home-based diagnostics where such resources are unavailable, isothermal amplification (e.g., using a recombinase polymerase amplification (RPA) system) is used in some implementations to complete the amplification step. RPA has been described in the literature and has been used in combination with LFT (RPA-LFT) for many diagnostic tests detecting nucleic acids in all types of sample sources. RPA-LFT can be configured to generate amplicons labeled with 6FAM and biotin, and thus can be elucidated on a lateral flow cassette. Primers used in conventional PCR can be used in RPA-LFT. Primers can be optimized for RPA-LFT using results from 6FAM-labeled and biotin-labeled AluYm1 amplicon primers used in conventional PCR-LFT. In most RPA-LFT applications, additional oligonucleotides, or "probes," are required. As with direct PNA-based methods, the detection limits of biomarkers can be determined using both synthetic dsDNA targets and purified genomic DNA.

[0100] The test can be validated in clinical studies in patients with SLE and other diseases. For example, at the start of the study, patients will be assessed using the AluYm1 amplicon test via established routine qPCR assays. AluYm1 amplicon levels can be monitored every 3 days for 3 months to obtain clinical performance data for the LFT test. This study can facilitate the early detection of disease exacerbations and the initiation of treatment using precision therapies to prevent disease progression and avoid the use of very aggressive corticosteroids and other high-dose immunosuppressive therapies during full-blown disease exacerbations.

[0101] Other nanoparticle options that could potentially improve sensitivity include gold-platinum nanoflowers and carbon nanoparticles. Other options for enhancing sensitivity include the use of fluorescent tags, some of which can be read by small portable readers or even smartphone cameras mounted on microscope lenses. Because the functional groups 6FAM and biotin exhibit a delicately balanced binding affinity, the binding of the composite analyte to the test line will be most significantly influenced by flow rate and mass transfer considerations, parameters that can be tuned by sieving different nitrocellulose papers.

[0102] Target abundance can be achieved using isothermal amplification protocols, but some techniques may be affected by nonspecific amplification. To address this, chemically modified oligonucleotide primers (e.g., PNA) can be used to impart greater specificity.

[0103] In some implementations, using blood as a sample matrix may be less desirable (e.g., due to the need for cell separation and the potential for low-abundance targets in capillary blood). Since biomarkers are present in urine, and LFT technology is preferentially applied to the elucidation of nucleic acids in urine, particularly for lupus patients with nephritis, using urine for LFT may be desirable in some implementations.

[0104] In some implementations, combinations of multiple biomarkers are used for the diagnosis and targeted therapy of SLE. For example, treatments like afluloxacin have shown promise in clinical trials, providing an encouraging precedent for biomarker-driven treatment strategies when administered to patients identified with specific interferon (IFN) signatures. Building on this, DxTerity Diagnostics (Rancho Dominguez, CA) has developed an IFN-1 gene signature test specifically designed for patients with SLE, aiming to identify those at high risk of developing severe disease and unlikely to respond to standard treatments.

[0105] sequence target shared sequence ALUSP common sequence (SEQ ID NO: 1): GGCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA ALUYH3 consensus sequence (SEQ ID NO: 2): GGCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCAGAGGCGGGCGGATCATGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGCCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA ALUYM1 consensus sequence (SEQ ID NO: 3): GGCCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA L1M1 consensus sequence (SEQ ID NO: 4): L1PB common sequence (SEQ ID NO: 5): L1P4 common sequence (SEQ ID NO: 6): Primer sequence AluSp primer array TTTTGTATTTTTAGTAGAGACGGGGT (SEQ ID NO: 7) AGCCTGACCAACATGGAGAA (SEQ ID NO: 8) GGTCTCGAACTCCCGACC (SEQ ID NO: 9) CGGGCGGATCACCTGA (SEQ ID NO: 10) GCCTCGGCCTCCCAAA (SEQ ID NO: 11) ACGCCTGTAATCCCAGCA (SEQ ID NO: 12) TAGCCGGGCGTGGTG (SEQ ID NO: 13) TGGGATTACAGGCATGCG (SEQ ID NO: 14) GCTACTCGGGAGGCTGA (SEQ ID NO: 15) GGTTCAAGCGATTCTCCTGC (SEQ ID NO: 16) CGGGAGGCGGAGGT (SEQ ID NO: 17) TCTCGGCTCACCGCA (SEQ ID NO: 18) TCGCGCCATTGCACTC (SEQ ID NO: 19) CTCTTGTTGCCCAGGCTG (SEQ ID NO: 20) GGCGCGGTGGCTC (SEQ ID NO: 21) TGCTGGGATTACAGGCGT (SEQ ID NO: 22) CTTTGGGAGGCCGAGG (SEQ ID NO: 23) TCAGGTGATCCGCCCG (SEQ ID NO: 24) GGTCGGGAGTTCGAGACC (SEQ ID NO: 25) TTCTCCATGTTGGTCAGGCT (SEQ ID NO: 26) ACCCCGTCTCTACTAAAAATACAAAA (SEQ ID NO: 27) ACCACGCCCGGCTA (SEQ ID NO: 28) CATGCCTGTAATCCCAGCTAC (SEQ ID NO: 29) CCTCAGCCTCCCGAGT (SEQ ID NO: 30) CAGGAGAATCGCTTGAACCC (SEQ ID NO: 31) GCAACCTCCGCCTCC (SEQ ID NO: 32) TGCGGTGAGCCGAGA (SEQ ID NO: 33) GAGTGCAATGGCGCGA (SEQ ID NO: 34) CAGCCTGGGCAACAAGAG (SEQ ID NO: 35) TTTTTTTTTTTTTGAGACGGAGTTTCG (SEQ ID NO: 36) AluY1m primer array TTTTTTTTTTGAGACGGAGTCTCG (SEQ ID NO: 37) AGCCTGGGCGACAGAG (SEQ ID NO: 38) CTCTGTCGCCCAGGCT (SEQ ID NO: 39) TCGCGCCACTGCACT (SEQ ID NO: 40) AGTGCAGTGGCGCGA (SEQ ID NO: 41) GCTTGCAGTGAGCCGAGA (SEQ ID NO: 42) TCTCGGCTCACTGCAAGC (SEQ ID NO: 43) TGAACCCGGGAGGCG (SEQ ID NO: 44) CGCCTCCCGGGTTCA (SEQ ID NO: 45) TGAGGCAGGAGAATGGCG (SEQ ID NO: 46) CGCCATTCTCCTGCCTC (SEQ ID NO: 47) CAGCTACTCGGGAGGCT (SEQ ID NO: 48) GCCTCCCGAGTAGCTGG (SEQ ID NO: 49) GCGGGCGCCTGTAGTC (SEQ ID NO: 50) GACTACAGGCGCCCGC (SEQ ID NO: 51) AGCCGGGCGTGGTG (SEQ ID NO: 52) ACCACGCCCGGCT (SEQ ID NO: 53) CCCCGTCTCTACTAAAAATACAAAAAATT (SEQ ID NO: 54) AATTTTTTGTATTTTTAGTAGAGACGGGG (SEQ ID NO: 55) CCTGGCTAACACGGTGAAA (SEQ ID NO: 56) TTTCACCGTGTTAGCCAGG (SEQ ID NO: 57) GGTCAGGAGATCGAGACCAT (SEQ ID NO: 58) ATGGTCTCGATCTCCTGACC (SEQ ID NO: 59) GCGGGCGGATCACG (SEQ ID NO: 60) TCGTGATCCGCCCGC (SEQ ID NO: 61) CACTTTGGGAGGCCGAG (SEQ ID NO: 62) CTCGGCCTCCCAAAGTG (SEQ ID NO: 63) GCTCAAGCCTGTAATCCCAG (SEQ ID NO: 64) CTGGGATTACAGGCTTGAGC (SEQ ID NO: 65) CCGGGCGCGGTG (SEQ ID NO: 66) L1M1 primer array (61 primers) ATGTTGAGCACCTTTTCATATGC (SEQ ID NO: 67) TTCTCAAAAGAAGACATACAAATGGC (SEQ ID NO: 68) ATGTCTATTCAGATCTTTTGCCCA (SEQ ID NO: 69) ATAGGAAAAAATCTAATCCGATTAAAAAATG (SEQ ID NO: 70) GAGTTGTTTGAGCTCCTTATATTCTG (SEQ ID NO: 71) ACTACCCATCTGACAAGGGAT (SEQ ID NO: 72) TTGCAAATATTTTCTCCCATTCTGT (SEQ ID NO: 73) GAAACAATCAAAAGTGAAGAGACA (SEQ ID NO: 74) CTTTGCTGTGCAGAAGCTTTT (SEQ ID NO: 75) AGCAAAAATGGACAAATGGGATC (SEQ ID NO: 76) TTGGTTGCCTGTGCTTGT (SEQ ID NO: 77) GGTCTGGGCAAAGATTTCTTGA (SEQ ID NO: 78) CAATGTCCTGGAGAGTTTCCC (SEQ ID NO: 79) AACTATGAAACTACTACAAGAAAACATTGG (SEQ ID NO: 80) TGAGGTCTTAGATTTAAGTCTTTAATCCA (SEQ ID NO: 81) TCGCCATACAAAAATCAAATCAAAATG (SEQ ID NO: 82) TTGTATATGGCGAGAGATAGGGG (SEQ ID NO: 83) ATTACHMENTGAAGAAGAAGAA (SEQ ID NO: 84) CCAGTTTTCCCAGCACCAT (SEQ ID NO: 85) TACACTGGGGAAAAGACAGTCT (SEQ ID NO: 86) TGTTCTTGGCACCTTTGTCG (SEQ ID NO: 87) AAATCCACACACCTACAGTGAAC (SEQ ID NO: 88) GTTTCTGGGTTCTCTATTCTGTTCC (SEQ ID NO: 89) GCATAAAACAGACACATAGACCAAT (SEQ ID NO: 90) DOCUMENTGCTGTTTTGGTTAC (SEQ ID NO: 91) TGACTTCAAATTACTACAGAGCTATAGT (SEQ ID NO: 92) CAGGTAATGTGATTCCTCCAGTT (SEQ ID NO: 93) CCAAAGCTATCCTGAGCAAAAAG (SEQ ID NO: 94) TATTCTGGGTCTTTTGTGGTTCC (SEQ ID NO: 95) SEQ ID NO: 96 TGAAGAATGTCATTGGTATTTTGATAGG (SEQ ID NO: 97) GCAATCTACAGATTCAATGCAATCC (SEQ ID NO: 98) TGCTTTGGGTAGTATGGACATTTTA (SEQ ID NO: 99) GTTCATGGATTGGAAGAATCAATATTGT (SEQ ID NO: 100) ATGGAATATCTTTCCATTTTTTGGTGT (SEQ ID NO: 101) AACACTGATGAAAGAAATTGAAGAGG (SEQ ID NO: 102) CATCAGTGTTTTATAGTTTTCATTGTAGAGA (SEQ ID NO: 103) TTAACTTAACCAAAGAAGTGAAAGATCTC (SEQ ID NO: 104) TTCCTAGGTATTTAATTTTTTGTGGCTA (SEQ ID NO: 105) ATCAAAAAAGTAATCCCATTTACAATAGC (SEQ ID NO: 106) GATTTCTTTTTCAGATTGTTCACTGTTG (SEQ ID NO: 107) CAAAAATCAGTAGCATTTCTATATGCCA (SEQ ID NO: 108) TATGTTGATTTTGTATCCTGCAACTT (SEQ ID NO: 109) ACCOUNTING ACTGATAAACAAATTCAGTAAAG (SEQ ID NO: 110) GTGGAGTCTTTAGGTTTTTCCAAAT (SEQ ID NO: 111) CCTTGTTTGCAGATGATATGATCTTAT (SEQ ID NO: 112) ATAATTTGACTTCTTCCTTTCCAATTTG (SEQ ID NO: 113) GACAAGAAAGAAAATAAAGGGCATC (SEQ ID NO: 114) GTCTGATTGCTCTAGCTAGGACT (SEQ ID NO: 115) TTTCACCACTGTTATTCAACATAGTACTGG (SEQ ID NO: 116) GTGGGCATCCTTGTCGTG (SEQ ID NO: 117) AAAACTGAAAGCCTTTCCTCTAAGA (SEQ ID NO: 118) AGTTTTTCCCCATTCAGTGATACTAG (SEQ ID NO: 119) AAAAGCCATATACGACAGACCC (SEQ ID NO: 120) CTTTTATTATGTTGAGGTATGTTCCTTCTATA (SEQ ID NO: 121) TAAAAACCCTCAAAAAACTGGGTATAG (SEQ ID NO: 122) GGTTTTTATCATGAAGGGATGTTGAAT (SEQ ID NO: 123) CAATTGATGCTGAAAAAGCATTTGAT (SEQ ID NO: 124) GAAATGATCATATGGTTTTTGTCCTTCA (SEQ ID NO: 125) CAATGTGATACATCATATCAACAGAATGAA (SEQ ID NO: 126) TGATGTATCACATTGATTGATTTGCG (SEQ ID NO: 127) Type A amplicon <150 base pairs Assay 001 (SEQ ID NO: 128) TTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 002 (SEQ ID NO: 129) ATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 003 (SEQ ID NO: 130) ATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 004 (SEQ ID NO: 131) ACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 005 (SEQ ID NO: 132) ACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 006 (SEQ ID NO: 133) GAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 007 (SEQ ID NO: 134) GAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 008 (SEQ ID NO: 135) AGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 009 (SEQ ID NO: 136) AGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 010 (SEQ ID NO: 137) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 011 (SEQ ID NO: 138) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 012 (SEQ ID NO: 139) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 013 (SEQ ID NO: 140) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 014 (SEQ ID NO: 141) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 015 (SEQ ID NO: 142) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 016 (SEQ ID NO: 143) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 017 (SEQ ID NO: 144) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 018 (SEQ ID NO: 145) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 019 (SEQ ID NO: 146) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Determinant 020 (SEQ ID NO: 147) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Determinant 021 (SEQ ID NO: 148) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determinant 022 (SEQ ID NO: 148) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determinant 023 (SEQ ID NO: 150) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determinant 024 (SEQ ID NO: 151) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determinant 025 (SEQ ID NO: 152) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Determinant 026 (SEQ ID NO: 153) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Determinant 027 (SEQ ID NO: 154) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Assay 028 (SEQ ID NO: 155) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Assay 029 (SEQ ID NO: 156) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Assay 030 (SEQ ID NO: 157) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Assay 031 (SEQ ID NO: 158) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Assay 032 (SEQ ID NO: 159) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Assay 033 (SEQ ID NO: 160) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Assay 034 (SEQ ID NO: 161) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Assay 035 (SEQ ID NO: 162) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 036 (SEQ ID NO: 163) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 037 (SEQ ID NO: 164) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Determination 038 (SEQ ID NO: 165) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Determination 039 (SEQ ID NO: 166) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Determination 040 (SEQ ID NO: 167) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Determination 041 (SEQ ID NO: 168) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Determination 042 (SEQ ID NO: 169) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Determination 043 (SEQ ID NO: 170) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Assay 044 (SEQ ID NO: 171) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Assay 045 (SEQ ID NO: 172) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATA Assay 046 (SEQ ID NO: 173) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATA Assay 047 (SEQ ID NO: 174) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCAC Assay 048 (SEQ ID NO: 175) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCAC Assay 049 (SEQ ID NO: 176) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT Assay 050 (SEQ ID NO: 177) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT Assay 051 (SEQ ID NO: 178) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGAC Assay 052 (SEQ ID NO: 179) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGAC Assay 053 (SEQ ID NO: 180) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCAC Assay 054 (SEQ ID NO: 181) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCAC Assay 055 (SEQ ID NO: 182) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCAC Assay 056 (SEQ ID NO: 183) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACT Assay 057 (SEQ ID NO: 184) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACT Assay 058 (SEQ ID NO: 185) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAG Determination 059 (SEQ ID NO: 186) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAG Determination 060 (SEQ ID NO: 187) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACC Determination 061 (SEQ ID NO: 188) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACC Determination 062 (SEQ ID NO: 189) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTC Determination 063 (SEQ ID NO: 190) AGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Determination 064 (SEQ ID NO: 191) TCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Determination 065 (SEQ ID NO: 192) GCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Determination 066 (SEQ ID NO: 193) TGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Assay 067 (SEQ ID NO: 194) TGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Assay 068 (SEQ ID NO: 195) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Assay 069 (SEQ ID NO: 196) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Assay 070 (SEQ ID NO: 197) TCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Assay 071 (SEQ ID NO: 198) GCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Assay 072 (SEQ ID NO: 199) TGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Assay 073 (SEQ ID NO: 200) TGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Assay 074 (SEQ ID NO: 201) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Assay 075 (SEQ ID NO: 202) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Assay 076 (SEQ ID NO: 203) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Assay 077 (SEQ ID NO: 204) GCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Assay 078 (SEQ ID NO: 205) TGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Assay 079 (SEQ ID NO: 206) TGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Assay 080 (SEQ ID NO: 207) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Determination 081 (SEQ ID NO: 208) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Determination 082 (SEQ ID NO: 209) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Determination 083 (SEQ ID NO: 210) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Determination 084 (SEQ ID NO: 211) TGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Determination 085 (SEQ ID NO: 212) TGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Determination 086 (SEQ ID NO: 213) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Determination 087 (SEQ ID NO: 214) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Determination 088 (SEQ ID NO: 215) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Determination 089 (SEQ ID NO: 216) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Determination 090 (SEQ ID NO: 217) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Determination 091 (SEQ ID NO: 218) TGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Determination 092 (SEQ ID NO: 219) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Determination 093 (SEQ ID NO: 220) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Determination 094 (SEQ ID NO: 221) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Assay 095 (SEQ ID NO: 222) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Assay 096 (SEQ ID NO: 223) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Assay 097 (SEQ ID NO: 224) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Assay 098 (SEQ ID NO: 225) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 099 (SEQ ID NO: 226) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 100 (SEQ ID NO: 227) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 101 (SEQ ID NO: 228) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 102 (SEQ ID NO: 229) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 103 (SEQ ID NO: 230) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 104 (SEQ ID NO: 231) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 105 (SEQ ID NO: 232) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Assay 106 (SEQ ID NO: 233) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Assay 107 (SEQ ID NO: 234) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Assay 108 (SEQ ID NO: 235) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Determination 109 (SEQ ID NO: 236) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Determination 110 (SEQ ID NO: 237) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Determination 111 (SEQ ID NO: 238) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Determination 112 (SEQ ID NO: 239) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Determination 113 (SEQ ID NO: 240) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Determination 114 (SEQ ID NO: 241) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Determination 115 (SEQ ID NO: 242) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Determination 116 (SEQ ID NO: 243) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Determination 117 (SEQ ID NO: 244) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Determination 118 (SEQ ID NO: 245) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Determination 119 (SEQ ID NO: 246) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGT Determination 120 (SEQ ID NO: 247) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGT Determination 121 (SEQ ID NO: 248) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGT Determination 122 (SEQ ID NO: 249) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGT Assay 123 (SEQ ID NO: 250) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGT Assay 124 (SEQ ID NO: 251) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGT Assay 125 (SEQ ID NO: 252) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGT Assay 126 (SEQ ID NO: 253) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATT Assay 127 (SEQ ID NO: 254) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATT Assay 128 (SEQ ID NO: 255) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATT Assay 129 (SEQ ID NO: 256) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATT Assay 130 (SEQ ID NO: 257) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATT Assay 131 (SEQ ID NO: 258) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATT Assay 132 (SEQ ID NO: 259) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAA Assay 133 (SEQ ID NO: 260) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAA Assay 134 (SEQ ID NO: 261) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAA Assay 135 (SEQ ID NO: 262) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAA Assay 136 (SEQ ID NO: 263) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAA Determination 137 (SEQ ID NO: 264) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCAT Determination 138 (SEQ ID NO: 265) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCAT Determination 139 (SEQ ID NO: 266) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCAT Determination 140 (SEQ ID NO: 267) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCAT Determination 141 (SEQ ID NO: 268) CACTTTGGGAGGCCGAGGCGGGCGGATCACGA Determination 142 (SEQ ID NO: 269) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGA Determination 143 (SEQ ID NO: 270) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGA Determination 144 (SEQ ID NO: 271) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAG Determination 145 (SEQ ID NO: 272) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAG Determination 146 (SEQ ID NO: 273) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAG Determination 147 (SEQ ID NO: 274) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAA Determination 148 (SEQ ID NO: 275) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAA Determination 149 (SEQ ID NO: 276) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAA Determination 150 (SEQ ID NO: 277) GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAA Determination 151 (SEQ ID NO: 278) CTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAA Determination 152 (SEQ ID NO: 279) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAA Determination 153 (SEQ ID NO: 280) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACC Determination 154 (SEQ ID NO: 281) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACC Determination 155 (SEQ ID NO: 282) GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACC Determination 156 (SEQ ID NO: 283) CTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACC Determination 157 (SEQ ID NO: 284) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGC Determination 158 (SEQ ID NO: 285) GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGC Determination 159 (SEQ ID NO: 286) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCA Determination 160 (SEQ ID NO: 287) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCA Determination 161 (SEQ ID NO: 288) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCA Assay 162 (SEQ ID NO: 289) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCA Assay 163 (SEQ ID NO: 290) CTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCA Assay 164 (SEQ ID NO: 291) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCA Assay 165 (SEQ ID NO: 292) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCA Assay 166 (SEQ ID NO: 293) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC Assay 167 (SEQ ID NO: 294) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC Assay 168 (SEQ ID NO: 295) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC Assay 169 (SEQ ID NO: 296) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC Assay 170 (SEQ ID NO: 297) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC Assay 171 (SEQ ID NO: 298) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC Assay 172 (SEQ ID NO: 299) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGA Assay 173 (SEQ ID NO: 300) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGA Assay 174 (SEQ ID NO: 301) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGA Assay 175 (SEQ ID NO: 302) CGGGAGGCGGAGGTTGCGGTGAGCCGAGA Assay 176 (SEQ ID NO: 303) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGA Assay 177 (SEQ ID NO: 304) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGA Assay 178 (SEQ ID NO: 305) CAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGA Assay 179 (SEQ ID NO: 306) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAG Assay 180 (SEQ ID NO: 307) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAG Assay 181 (SEQ ID NO: 308) CGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAG Assay 182 (SEQ ID NO: 309) TCGCGCCATTGCACTCCAGCCTGGGCAACAAGAG Assay 183 (SEQ ID NO: 310) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAG Assay 184 (SEQ ID NO: 311) CAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAG Assay 185 (SEQ ID NO: 312) TGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAG Assay 186 (SEQ ID NO: 313) GGCGCGGTGGCTCACGCCTGTAATCCCAGCA Assay 187 (SEQ ID NO: 314) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGA Assay 188 (SEQ ID NO: 315) GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGA Assay 189 (SEQ ID NO: 316) CTTTGGGAGGCCGAGGCGGGCGGATCACCTGA Assay 190 (SEQ ID NO: 317) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAA Assay 191 (SEQ ID NO: 318) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAA Assay 192 (SEQ ID NO: 319) GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAA Determination 193 (SEQ ID NO: 320) CTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAA Determination 194 (SEQ ID NO: 321) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAA Determination 195 (SEQ ID NO: 322) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGT Determination 196 (SEQ ID NO: 323) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGT Determination 197 (SEQ ID NO: 324) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGT Determination 198 (SEQ ID NO: 325) GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGT Determination 199 (SEQ ID NO: 326) CTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGT Determination 200 (SEQ ID NO: 327) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGT Determination 201 (SEQ ID NO: 328) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGT Determination 202 (SEQ ID NO: 329) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGG Determination 203 (SEQ ID NO: 330) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGG Determination 204 (SEQ ID NO: 331) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGG Determination 205 (SEQ ID NO: 332) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGG Determination 206 (SEQ ID NO: 333) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGG Determination 207 (SEQ ID NO: 334) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGG Determination 208 (SEQ ID NO: 335) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGC Determination 209 (SEQ ID NO: 336) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGC Determination 210 (SEQ ID NO: 337) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGC Determination 211 (SEQ ID NO: 338) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGC Determination 212 (SEQ ID NO: 339) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGC Determination 213 (SEQ ID NO: 340) CAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGC Determination 214 (SEQ ID NO: 341) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTC Assay 215 (SEQ ID NO: 342) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTC Assay 216 (SEQ ID NO: 343) CGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTC Assay 217 (SEQ ID NO: 344) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTC Assay 218 (SEQ ID NO: 345) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTC Assay 219 (SEQ ID NO: 346) CAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTC Assay 220 (SEQ ID NO: 347) TGCGGTGAGCCGAGATCGCGCCATTGCACTC Assay 221 (SEQ ID NO: 348) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAA Assay 222 (SEQ ID NO: 349) CGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAA Assay 223 (SEQ ID NO: 350) TCGCGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAA Assay 224 (SEQ ID NO: 351) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAA Assay 225 (SEQ ID NO: 352) CAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAA Assay 226 (SEQ ID NO: 353) TGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAA Assay 227 (SEQ ID NO: 354) CAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAA Type B amplicon >150 base pairs Assay 228 (SEQ ID NO: 355) ACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 229 (SEQ ID NO: 356) GAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 230 (SEQ ID NO: 357) AGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 231 (SEQ ID NO: 358) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Determinant 232 (SEQ ID NO: 359) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Determinant 233 (SEQ ID NO: 360) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Measurement 234 (SEQ ID NO: 361) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Measurement 235 (SEQ ID NO: 362) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Measurement 236 (SEQ ID NO: 363) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Determination 237 (SEQ ID NO: 364) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Determination 238 (SEQ ID NO: 365) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Measurement 239 (SEQ ID NO: 365) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Determination 240 (SEQ ID NO: 367) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Determination 241 (SEQ ID NO: 368) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Determination 242 (SEQ ID NO: 369) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Determination 243 (SEQ ID NO: 370) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Determination 244 (SEQ ID NO: 371) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGCACCAAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAACAATCCTAAATTTTATAGGAACCACAAAAAGCCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAACTGGAGGAATCACATTACCTGACTTCAAATTACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAACAGACACATAGACCAATGGAACCAGAATAGAGAACCCAGAAACAAATCCACACCACATGGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAGACAGTCTCTTCAATAA ATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTTCGCCATATACAAAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAATGGACAAATGGGACATCACATCAAGTTAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGGAAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAATCTAATAATCCGATTAAAAATGGCAAAAAGATCTGAATAGACATTTCTCAAAAAGAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCCAACAT Determination of 245 (SEQ ID NO: 372) Determination of 246 (SEQ ID NO: 373) Determination of 247 (SEQ ID NO: 374) Determination of 248 (SEQ ID NO: 375) Determination of 249 (SEQ ID NO: 376) Determination of 250 (SEQ ID NO: 377) Determination of 251 (SEQ ID NO: 378) Determination of 252 (SEQ ID NO: 379) Determination of 253 (SEQ ID NO: 380) Determination of 254 (SEQ ID NO: 381) Determination of 255 (SEQ ID NO: 382) Determination 256 (SEQ ID NO: 383) GAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Determination 257 (SEQ ID NO: 384) AGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Determination 258 (SEQ ID NO: 385) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Determination 259 (SEQ ID NO: 386) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Measurement 260 (SEQ ID NO: 387) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Measurement 261 (SEQ ID NO: 388) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Measurement 262 (SEQ ID NO: 389) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Measurement 263 (SEQ ID NO: 390) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Determination 264 (SEQ ID NO: 391) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Determination 265 (SEQ ID NO: 392) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Determination 266 (SEQ ID NO: 393) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Measurement 267 (SEQ ID NO: 394) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Determination 268 (SEQ ID NO: 395) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Determination 269 (SEQ ID NO: 396) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Determination 270 (SEQ ID NO: 397) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Determination 271 (SEQ ID NO: 398) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Determination 272 (SEQ ID NO: 399) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAAACTATAAAACACTGATGAAAGAAATTGAAGAGCACCAAAAAAATGGAAAGATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCTATCAAAATACCAATGACCATTTTATATCACACAGAAATAAAAACAATCCTAAAATTTGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAACTGGAGGAATCACATTACCTAGCTTCAAATTACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAACAGACACATAGACCAATGGAACCAATGGAACCAGAAATAGAGACCACAAACAAAATCCACACCACACACACTCAGAACTCAACTCAGTAACTCA TTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAAGATGAAACTAGACCCCTATCTTCGCCATATACAAAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAATGGACAAATGGGACATCACATCAAGTTAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGGAAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAATCTAATAATCCGATTAAAAATGGCAAAAAGATCTGAATAGACAT Determination of 273 (SEQ ID NO: 400) Determination of 274 (SEQ ID NO: 401) Determination of 275 (SEQ ID NO: 402) Determination of 276 (SEQ ID NO: 403) Determination of 277 (SEQ ID NO: 404) Determination of 278 (SEQ ID NO: 405) Determination of 279 (SEQ ID NO: 406) Determination of 280 (SEQ ID NO: 407) Determination of 281 (SEQ ID NO: 408) Determination of 282 (SEQ ID NO: 409) Determination 283 (SEQ ID NO: 410) AGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 284 (SEQ ID NO: 411) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 285 (SEQ ID NO: 412) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 286 (SEQ ID NO: 413) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 287 (SEQ ID NO: 414) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 288 (SEQ ID NO: 415) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 289 (SEQ ID NO: 416) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 290 (SEQ ID NO: 417) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 291 (SEQ ID NO: 418) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 292 (SEQ ID NO: 419) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Measurement of 293 (SEQ ID NO: 420) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 294 (SEQ ID NO: 421) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 295 (SEQ ID NO: 422) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 296 (SEQ ID NO: 423) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 297 (SEQ ID NO: 424) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Measurement 298 (SEQ ID NO: 425) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Determination 299 (SEQ ID NO: 426) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAAATCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAACTATAAAACACTGATGAAAGAAATTGAAGAGCACCAAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATTTGTTAAATTGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCTATCAAAATACCAATAGAAAACAATCCTAAATTTATAGGAACCACAAAAAGCCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAACTGGAGGAATCACATTACCTGACTTCAAATTACTACAGGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGAC AATGGAACAGAATAGAGAACCCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAAGATGAAACTAGACCCCTATCTTCGCCATATACAAAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGGAAACTCTCCAGGACATTGGTCGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAATGGACAAATGGGACATCACATCAAGTTAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCACT Determination of 300 (SEQ ID NO: 427) Determination of 301 (SEQ ID NO: 428) Determination of 302 (SEQ ID NO: 429) Determination of 303 (SEQ ID NO: 430) Determination of 304 (SEQ ID NO: 431) Determination of 305 (SEQ ID NO: 432) Determination of 306 (SEQ ID NO: 433) Determination of 307 (SEQ ID NO: 434) Determination of 308 (SEQ ID NO: 435) Determination 309 (SEQ ID NO: 436) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 310 (SEQ ID NO: 437) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 311 (SEQ ID NO: 438) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 312 (SEQ ID NO: 439) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determinant 313 (SEQ ID NO: 440) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determinant 314 (SEQ ID NO: 441) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 315 (SEQ ID NO: 442) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 316 (SEQ ID NO: 443) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determined 317 (SEQ ID NO: 444) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 318 (SEQ ID NO: 445) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 319 (SEQ ID NO: 446) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 320 (SEQ ID NO: 447) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 321 (SEQ ID NO: 448) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determinant 322 (SEQ ID NO: 449) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 323 (SEQ ID NO: 450) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 324 (SEQ ID NO: 451) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Determination 325 (SEQ ID NO: 452) ACATTTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAAATCTGAAAAAGAAAATCAAAAAAGTATCCCATTTACAATAGCCACAAATAAAATTAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAACTATAAAACACTGATGAAAGAAATTGAAGAGGAACCAAAAA ATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAATCAAATACCAATGACATTCTTCACAGAATAGAAAAACAATCTCAAAATTTTATATGGAACCACAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTAC AGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAAGATGAAACTAGACCCCTATCTCTGCCATATACAAAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGGAAACTCTCCAGGACATTGGTCGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAATGGACAAATGGGACATCACATCAAGTTAAAAAGCTCTGCACAGCAAAGGAAACAATCAAAGTCAACAAAGTGGAAGAGACAACCCACAGAATGGGAGAAAATTTGCAA Determination of 326 (SEQ ID NO: 453) Determination of 327 (SEQ ID NO: 454) Determination of 328 (SEQ ID NO: 455) Determination of 329 (SEQ ID NO: 456) Determination of 330 (SEQ ID NO: 457) Determination of 331 (SEQ ID NO: 458) Determination of 332 (SEQ ID NO: 459) Determination of 333 (SEQ ID NO: 460) Determination 334 (SEQ ID NO: 461) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 335 (SEQ ID NO: 462) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 336 (SEQ ID NO: 463) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 337 (SEQ ID NO: 464) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 338 (SEQ ID NO: 465) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 339 (SEQ ID NO: 466) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 340 (SEQ ID NO: 467) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 341 (SEQ ID NO: 468) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 342 (SEQ ID NO: 469) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 343 (SEQ ID NO: 470) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 344 (SEQ ID NO: 471) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 345 (SEQ ID NO: 472) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 346 (SEQ ID NO: 473) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 347 (SEQ ID NO: 474) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Measurement 348 (SEQ ID NO: 475) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Determination 349 (SEQ ID NO: 476) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Measurement 350 (SEQ ID NO: 477) CCTTGTTTGCAGATGATAATGATCTTATATTTGGAAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAAATCAAAAAAGTATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAAA TCTCTACAATGAAAAACTATAAACACTGATGAAAAAAATTGAAGAGGACACCAAAAATGAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAAATTTTATATGGAACCACAAAAGACCCAGAATACCAAAGCTATC CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAACAGACACATAGACCAATGGAACCAGAATAGAGAACCCCAGAAACAAATCCACACACTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCCAGAAAATGAAACTGAACCCCTATCTCTGCCATATACAAAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGGAAACTCTCCAGGACATTGGTCGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAATGGACAAATGGGATCACATCAAGTTAAAAGCTTCTGCACAGCAAAG Determination of 351 (SEQ ID NO: 478) Determination of 352 (SEQ ID NO: 479) Determination of 353 (SEQ ID NO: 480) Determination of 354 (SEQ ID NO: 481) Determination of 355 (SEQ ID NO: 482) Determination of 356 (SEQ ID NO: 483) Determination of 357 (SEQ ID NO: 484) Determination 358 (SEQ ID NO: 485) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 359 (SEQ ID NO: 486) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 360 (SEQ ID NO: 487) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 361 (SEQ ID NO: 488) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 362 (SEQ ID NO: 489) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 363 (SEQ ID NO: 490) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Measurement 364 (SEQ ID NO: 491) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Measurement 365 (SEQ ID NO: 492) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 366 (SEQ ID NO: 493) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 367 (SEQ ID NO: 494) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 368 (SEQ ID NO: 495) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 369 (SEQ ID NO: 496) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 370 (SEQ ID NO: 497) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 371 (SEQ ID NO: 498) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 372 (SEQ ID NO: 499) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 373 (SEQ ID NO: 500) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination 374 (SEQ ID NO: 501) GACAAGAAAAAAAATAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTTATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAGAAAATCAAAAAAGTATCCCATTTACAAAT AGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAAGAAGTGAAAGATCTCTACAATGAAACTATAAAACACTGAATGAAAGAAATTGAAGAGGACACAAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCACTACTACCCAAAGCAATCTACAGATTCAATGCAATCCTAAAAATACCAATGACATTCTTCACAGAAAAAAAA ACAATCCTAAATTTATATGGAACCACAAAAAGACCCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAACTGGAGGAATCACATTACCTGACTTCAAATTACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACCAGAATAGAGAACCCCAGAAACAAATCCACACACCACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCCAGAAAAGATGAAACTAGACCCCTATCTTCGCCATATACAAAAATCAAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGGAAACTCTCCAGGACATTGGTCGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Determination of 375 (SEQ ID NO: 502) Determination of 376 (SEQ ID NO: 503) Determination of 377 (SEQ ID NO: 504) Determination of 378 (SEQ ID NO: 505) Determination of 379 (SEQ ID NO: 506) Measurement of 380 (SEQ ID NO: 507) Assay 381 (SEQ ID NO: 508) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 382 (SEQ ID NO: 509) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 383 (SEQ ID NO: 510) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 384 (SEQ ID NO: 511) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Determination 385 (SEQ ID NO: 512) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Determination 386 (SEQ ID NO: 513) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Determination 387 (SEQ ID NO: 514) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Determination 388 (SEQ ID NO: 515) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Measurement 389 (SEQ ID NO: 516) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Determination 390 (SEQ ID NO: 517) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Determination 391 (SEQ ID NO: 518) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Determination 392 (SEQ ID NO: 519) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Determination 393 (SEQ ID NO: 520) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Determination 394 (SEQ ID NO: 521) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Determination 395 (SEQ ID NO: 522) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Determination 396 (SEQ ID NO: 523) TTTCACCACTGTTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAAAAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTTCCTTGTTTGCAGATGATATGATCTTATATTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATAAAAAATCAGTAGCATTTCTATATGC CAACAGTGAACAATCTGAAAAAGAAAATCAAAAAAGTATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGCCATACTACCCAAAGCAATCTACAGATTCA ATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAACAATCCTAAATTTATATGGAACCACAAAAAGACCCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAACTGGAGGAATCACATTACCTGACTTCAAATTACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACCAGAATAGAGAACCCCAGAAACAAATCCACACACCACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCCAGAAAAGATGAAACTAGACCCCTATCTTCGCCATATACAAAAATCAAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTCAAGAAAAACATTGGGGAAACTCTCCAGGACATTG Determination of 397 (SEQ ID NO: 524) Determination of 398 (SEQ ID NO: 525) Determination of 399 (SEQ ID NO: 526) Determination of 400 (SEQ ID NO: 527) Determination of 401 (SEQ ID NO: 528) Assay 402 (SEQ ID NO: 529) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 403 (SEQ ID NO: 530) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 404 (SEQ ID NO: 531) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 405 (SEQ ID NO: 532) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination 406 (SEQ ID NO: 533) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination 407 (SEQ ID NO: 534) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination 408 (SEQ ID NO: 535) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determined 409 (SEQ ID NO: 536) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination 410 (SEQ ID NO: 537) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination 411 (SEQ ID NO: 538) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination 412 (SEQ ID NO: 539) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination 413 (SEQ ID NO: 540) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination 414 (SEQ ID NO: 541) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination 415 (SEQ ID NO: 542) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination 416 (SEQ ID NO: 543) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination 417 (SEQ ID NO: 544) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCGACAAGAGAAAGAAATAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAA GTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAAATCAAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAAGAGTGAAAGATCTCTACAATGAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACAAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAG AATCAATATTGTTAAAATGTCCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAACAATCCTAAATTTATATGGAACCACAAAAAGCCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAACTGGAGGAATCACATTACCTGACTTCAAATTACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAACAGAATAGAGAACCCCAGAAACAAATCCACACACTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATTGCAGAAAATGAAACTGAACCCCTATCTTCGCCATATACAAAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAGCCCTATCAAGCCCTATCAAGCCCTATCAAAAATCAAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Determination of 418 (SEQ ID NO: 545) Determination of 419 (SEQ ID NO: 546) Determination of 420 (SEQ ID NO: 547) Determination of 421 (SEQ ID NO: 548) Assay 422 (SEQ ID NO: 549) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 423 (SEQ ID NO: 550) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 424 (SEQ ID NO: 551) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 425 (SEQ ID NO: 552) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 426 (SEQ ID NO: 553) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 427 (SEQ ID NO: 554) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 428 (SEQ ID NO: 555) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 429 (SEQ ID NO: 556) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Determination 430 (SEQ ID NO: 557) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Measurement 431 (SEQ ID NO: 558) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Determination 432 (SEQ ID NO: 559) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Determination 433 (SEQ ID NO: 560) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Determination 434 (SEQ ID NO: 561) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Determination 435 (SEQ ID NO: 562) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 436 (SEQ ID NO: 563) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Determination 437 (SEQ ID NO: 564) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Determination 438 (SEQ ID NO: 565) AAAAGCCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATAGATCTTATATTTGGAAAAAACCTA AAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAAAAATCAAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAACACTGAATGAAAAAAATTAAAG AGGACACCAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAACAATCCTAAATTTATATGGAACCACAAAAAGCCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAACTGGAGGAATCACATTACCTGACTTCAAATTACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAACAGACACATAGACCAATGGAACGAAATAGAGAACCCAGAAACAAATCCACACACTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCCAGAAAAGATGAAACTGACCCCTATCTCTCGCCATATACAA Determination of 439 (SEQ ID NO: 566) Determination of 440 (SEQ ID NO: 567) Determination of 441 (SEQ ID NO: 568) Determination 442 (SEQ ID NO: 569) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 443 (SEQ ID NO: 570) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 444 (SEQ ID NO: 571) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 445 (SEQ ID NO: 572) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 446 (SEQ ID NO: 573) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 447 (SEQ ID NO: 574) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Measurement 448 (SEQ ID NO: 575) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Measurement 449 (SEQ ID NO: 576) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Measurement 450 (SEQ ID NO: 577) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 451 (SEQ ID NO: 578) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 452 (SEQ ID NO: 579) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 453 (SEQ ID NO: 580) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 454 (SEQ ID NO: 581) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 455 (SEQ ID NO: 582) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 456 (SEQ ID NO: 583) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 457 (SEQ ID NO: 584) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination 458 (SEQ ID NO: 585) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGT GAAAGATCCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAG CTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Determination of 459 (SEQ ID NO: 586) Determination of 460 (SEQ ID NO: 587) Determination 461 (SEQ ID NO: 588) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 462 (SEQ ID NO: 589) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 463 (SEQ ID NO: 590) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 464 (SEQ ID NO: 591) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 465 (SEQ ID NO: 592) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 466 (SEQ ID NO: 593) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 467 (SEQ ID NO: 594) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 468 (SEQ ID NO: 595) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 469 (SEQ ID NO: 596) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Measurement 470 (SEQ ID NO: 597) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 471 (SEQ ID NO: 598) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 472 (SEQ ID NO: 599) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Measurement 473 (SEQ ID NO: 600) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Measurement 474 (SEQ ID NO: 601) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 475 (SEQ ID NO: 602) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Assay 476 (SEQ ID NO: 603) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination 477 (SEQ ID NO: 604) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Determination of 478 (SEQ ID NO: 605) Assay 479 (SEQ ID NO: 606) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Assay 480 (SEQ ID NO: 607) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Assay 481 (SEQ ID NO: 608) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Assay 482 (SEQ ID NO: 609) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Assay 483 (SEQ ID NO: 610) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Assay 484 (SEQ ID NO: 611) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Assay 485 (SEQ ID NO: 612) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Assay 486 (SEQ ID NO: 613) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Determination 487 (SEQ ID NO: 614) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Determination 488 (SEQ ID NO: 615) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Determination 489 (SEQ ID NO: 616) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Measurement at 490 (SEQ ID NO: 617) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Determination 491 (SEQ ID NO: 618) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Measurement 492 (SEQ ID NO: 619) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Determination 493 (SEQ ID NO: 620) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Determination 494 (SEQ ID NO: 621) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Determination 495 (SEQ ID NO: 622) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Assay 496 (SEQ ID NO: 623) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Assay 497 (SEQ ID NO: 624) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Assay 498 (SEQ ID NO: 625) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Assay 499 (SEQ ID NO: 626) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 500 (SEQ ID NO: 627) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 501 (SEQ ID NO: 628) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 502 (SEQ ID NO: 629) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 503 (SEQ ID NO: 630) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 504 (SEQ ID NO: 631) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 505 (SEQ ID NO: 632) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 506 (SEQ ID NO: 633) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 507 (SEQ ID NO: 634) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 508 (SEQ ID NO: 635) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 509 (SEQ ID NO: 636) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 510 (SEQ ID NO: 637) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 511 (SEQ ID NO: 638) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Determination 512 (SEQ ID NO: 639) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 513 (SEQ ID NO: 640) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 514 (SEQ ID NO: 641) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 515 (SEQ ID NO: 642) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 516 (SEQ ID NO: 643) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 517 (SEQ ID NO: 644) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 518 (SEQ ID NO: 645) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 519 (SEQ ID NO: 646) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 520 (SEQ ID NO: 647) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 521 (SEQ ID NO: 648) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 522 (SEQ ID NO: 649) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 523 (SEQ ID NO: 650) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 524 (SEQ ID NO: 651) TAAAAACCCTCAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAA TCAGACAAGAGAAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATG CCAACAGTGAACAATCTGAAAAGAAAATCAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAATGGAAAGATATTCCATGTTCATGGATTGGAA GAATCAATATTGTTAAAATGTCCACTACCAAAGCAATCTACAGATTCAATGCAATCCTATCAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCTCTAAAATTTTATATGGAACCACAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 525 (SEQ ID NO: 652) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 526 (SEQ ID NO: 653) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Determination 527 (SEQ ID NO: 654) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Determination 528 (SEQ ID NO: 655) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Determination 529 (SEQ ID NO: 656) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Determination 530 (SEQ ID NO: 657) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Determination 531 (SEQ ID NO: 658) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Determination 532 (SEQ ID NO: 659) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Assay 533 (SEQ ID NO: 660) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Assay 534 (SEQ ID NO: 661) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Determination 535 (SEQ ID NO: 662) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Measurement 536 (SEQ ID NO: 663) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Determination 537 (SEQ ID NO: 664) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Determination 538 (SEQ ID NO: 665) TAAAAACCCTCAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGCAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTC CTAGCTAGAGCAATCAGACAAGAGAAAAGAAATAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATAATGATCTTATATTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACAT ACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAGAAAATCAAAAAAGTATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACA CCAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAATCAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTTATATGGAACCACAAAGACCCAGAATA Determination 539 (SEQ ID NO: 666) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Determination 540 (SEQ ID NO: 667) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Determination 541 (SEQ ID NO: 668) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determination 542 (SEQ ID NO: 669) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determination 543 (SEQ ID NO: 670) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determination 544 (SEQ ID NO: 671) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determination 545 (SEQ ID NO: 672) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determination 546 (SEQ ID NO: 673) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determination 547 (SEQ ID NO: 674) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determination 548 (SEQ ID NO: 675) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determination 549 (SEQ ID NO: 676) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Measurement 550 (SEQ ID NO: 677) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determination 551 (SEQ ID NO: 678) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determination 552 (SEQ ID NO: 679) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determinant 553 (SEQ ID NO: 680) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Determination 554 (SEQ ID NO: 681) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 555 (SEQ ID NO: 682) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 556 (SEQ ID NO: 683) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 557 (SEQ ID NO: 684) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 558 (SEQ ID NO: 685) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 559 (SEQ ID NO: 686) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 560 (SEQ ID NO: 687) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 561 (SEQ ID NO: 688) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 562 (SEQ ID NO: 689) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 563 (SEQ ID NO: 690) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 564 (SEQ ID NO: 691) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 565 (SEQ ID NO: 692) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Determination 566 (SEQ ID NO: 693) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Determination 567 (SEQ ID NO: 694) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Measurement 568 (SEQ ID NO: 695) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Measurement 569 (SEQ ID NO: 696) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Measurement 570 (SEQ ID NO: 697) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Determination 571 (SEQ ID NO: 698) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Determination 572 (SEQ ID NO: 699) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Determination 573 (SEQ ID NO: 700) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Measurement 574 (SEQ ID NO: 701) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Measurement 575 (SEQ ID NO: 702) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Determination 576 (SEQ ID NO: 703) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Determination 577 (SEQ ID NO: 704) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Determination 578 (SEQ ID NO: 705) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Determination 579 (SEQ ID NO: 706) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Determination 580 (SEQ ID NO: 707) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Determination 581 (SEQ ID NO: 708) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Determination 582 (SEQ ID NO: 709) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Determination 583 (SEQ ID NO: 710) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Determination 584 (SEQ ID NO: 711) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Determination 585 (SEQ ID NO: 712) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Measurement 586 (SEQ ID NO: 713) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Determination 587 (SEQ ID NO: 714) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Determination 588 (SEQ ID NO: 715) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Determination 589 (SEQ ID NO: 716) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Determination 590 (SEQ ID NO: 717) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Determination 591 (SEQ ID NO: 718) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Determination 592 (SEQ ID NO: 719) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Determination 593 (SEQ ID NO: 720) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Measurement 594 (SEQ ID NO: 721) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Determination 595 (SEQ ID NO: 722) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Determination 596 (SEQ ID NO: 723) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Determination 597 (SEQ ID NO: 724) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Determination 598 (SEQ ID NO: 725) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Determination 599 (SEQ ID NO: 726) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Determination 600 (SEQ ID NO: 727) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Determination 601 (SEQ ID NO: 728) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Determination 602 (SEQ ID NO: 729) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Determination 603 (SEQ ID NO: 730) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Determination 604 (SEQ ID NO: 731) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATA Determination 605 (SEQ ID NO: 732) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATA Determination 606 (SEQ ID NO: 733) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATA Determination 607 (SEQ ID NO: 734) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATA Determination 608 (SEQ ID NO: 735) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATA Determination 609 (SEQ ID NO: 736) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATA Determination 610 (SEQ ID NO: 737) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATA Assay 611 (SEQ ID NO: 738) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCAC Assay 612 (SEQ ID NO: 739) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCAC Assay 613 (SEQ ID NO: 740) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCAC Determination 614 (SEQ ID NO: 741) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCAC Determination 615 (SEQ ID NO: 742) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCAC Assay 616 (SEQ ID NO: 743) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCAC Assay 617 (SEQ ID NO: 744) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT Determinant 618 (SEQ ID NO: 745) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT Determinant 619 (SEQ ID NO: 746) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT Determinant 620 (SEQ ID NO: 747) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT Determination 621 (SEQ ID NO: 748) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT Determination 622 (SEQ ID NO: 749) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGAC Determination 623 (SEQ ID NO: 750) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGAC Determination 624 (SEQ ID NO: 751) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGAC Determination 625 (SEQ ID NO: 752) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGAC Determination 626 (SEQ ID NO: 753) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCAC Measurement 627 (SEQ ID NO: 754) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCAC Measurement 628 (SEQ ID NO: 755) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACT Measurement 629 (SEQ ID NO: 756) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACT Measurement 630 (SEQ ID NO: 757) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAG Determination 631 (SEQ ID NO: 758) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Determination 632 (SEQ ID NO: 759) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Determination 633 (SEQ ID NO: 760) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Determination 634 (SEQ ID NO: 761) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Assay 635 (SEQ ID NO: 762) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Assay 636 (SEQ ID NO: 763) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Assay 637 (SEQ ID NO: 764) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Determination 638 (SEQ ID NO: 765) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Determination 639 (SEQ ID NO: 766) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Determination 640 (SEQ ID NO: 767) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Determination 641 (SEQ ID NO: 768) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Determination 642 (SEQ ID NO: 769) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Determination 643 (SEQ ID NO: 770) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Determinant 644 (SEQ ID NO: 771) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Determinant 645 (SEQ ID NO: 772) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Determinant 646 (SEQ ID NO: 773) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Determinant 647 (SEQ ID NO: 774) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Determination 648 (SEQ ID NO: 775) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Determination 649 (SEQ ID NO: 776) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Determination 650 (SEQ ID NO: 777) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Assay 651 (SEQ ID NO: 778) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Assay 652 (SEQ ID NO: 779) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Assay 653 (SEQ ID NO: 780) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Assay 654 (SEQ ID NO: 781) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Determination 655 (SEQ ID NO: 782) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Determination 656 (SEQ ID NO: 783) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Determination 657 (SEQ ID NO: 784) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Determination 658 (SEQ ID NO: 785) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Determination 659 (SEQ ID NO: 786) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Determination 660 (SEQ ID NO: 787) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Determination 661 (SEQ ID NO: 788) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Determination 662 (SEQ ID NO: 789) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Determination 663 (SEQ ID NO: 790) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Determination 664 (SEQ ID NO: 791) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Determination 665 (SEQ ID NO: 792) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Determination 666 (SEQ ID NO: 793) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCC...

Claims

1. A method for detecting biomarkers of inflammatory diseases, the method comprising determining the level of DNA fragments of genomic repetitive elements in a subject sample.

2. The method of claim 1, wherein the DNA fragment is derived from AluYm1.

3. The method of claim 2, wherein the DNA fragment derived from AluYm1 is less than about 300 bp.

4. The method of claim 2 or 3, wherein the DNA fragment derived from AluYm1 is about 200 bp or less than about 150 bp.

5. The method of any one of claims 2 to 4, wherein the DNA fragment derived from AluYm1 comprises a nucleotide sequence represented substantially by a nucleotide sequence selected from SEQ ID NO: 128-136, including its natural variants.

6. The method of any one of claims 1 to 5, wherein the DNA fragment is amplified from the sample or detected after direct capture.

7. The method of claim 6, wherein the DNA fragment is amplified by PCR, optionally using forward and reverse primers selected from SEQ ID NO: 7-127, wherein the forward primer has a nucleotide sequence selected from SEQ ID NO: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 and 66, and the reverse primer has a nucleotide sequence selected from SEQ ID NO: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63 and 65.

8. The method of claim 7, wherein the DNA fragment is quantified by qPCR, optionally using a TAQMAN or similar real-time PCR system.

9. The method of claim 6, wherein the DNA fragment is amplified by isothermal amplification, and optionally wherein the isothermal amplification is recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), or single primer isothermal amplification (SPIA).

10. The method of claim 9, wherein the isothermal amplification employs a forward primer and an optional reverse primer, the forward primer having a nucleobase sequence selected from SEQ ID NO: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 and 66, and the reverse primer having a nucleobase sequence selected from SEQ ID NO: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63 and 65.

11. The method of claim 9 or 10, wherein the DNA fragment is detected and / or quantified by a lateral flow assay.

12. The method of claim 11, wherein the DNA fragment is amplified using one or more primers conjugated to a detectable marker and a capture portion.

13. The method of any one of claims 1 to 12, wherein the elevated level of the DNA fragment indicates an active inflammatory disease in the subject.

14. The method of claim 13, wherein the inflammatory disease is an autoimmune disease.

15. The method of claim 14, wherein the autoimmune disease is systemic lupus erythematosus (SLE), and optionally involves lupus nephritis.

16. The method of claim 14 or 15, wherein the subject has a loss-of-function mutation in one or both DNAase 1l3 genes.

17. The method of claim 14, wherein the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, vasculitis, inflammatory bowel disease, and dermatomyositis.

18. The method of claim 13, wherein the inflammatory disease is gout.

19. The method of any one of claims 1 to 18, wherein the subject suffers from or is at risk of thrombotic vascular disease, myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism, and sepsis.

20. The method of any one of claims 1 to 19, wherein the sample is blood, serum, plasma or urine.

21. The method of any one of claims 1 to 20, wherein the subject is tested at a frequency of approximately once a day to approximately once a month.

22. A method for treating an inflammatory disease in a subject, the method comprising: Treatment is administered for the inflammatory disease, wherein the subject exhibits elevated levels of DNA fragments derived from repetitive DNA elements in a biological sample.

23. The method of claim 22, wherein the treatment is a DNA enzyme treatment.

24. The method of claim 23, wherein the treatment is extraintestinal DNA enzyme therapy.

25. The method of claim 23 or 24, wherein the DNase is DNase 1, DNase 1 sample 1, DNase 1 sample 2, or DNase 1 sample 3.

26. The method of claim 25, wherein the DNase is DNase 1-like 3 (D1L3), and optionally it is fused directly or indirectly to a carrier protein at its N-terminus via a linker, and wherein the carrier protein is optionally albumin.

27. The method of claim 25 or 26, wherein the D1L3 enzyme has a complete or partial deletion of the C-terminal basic domain.

28. The method of any one of claims 22 to 27, wherein the treatment comprises administering an immunosuppressive drug.

29. The method of claim 28, wherein the treatment comprises one or more of corticosteroids, azathioprine, mycophenolate mofetil, cyclophosphamide, vorciclosporine, belimumab, and afluromab.

30. The method of any one of claims 22 to 29, wherein the DNA fragment is greater than 150 base pairs (bp).

31. The method of claim 30, wherein the DNA fragment is derived from AluYm1 and is less than about 300 bp.

32. The method of claim 31, wherein the DNA fragment derived from AluYm1 is about 200 bp, or the DNA fragment is less than about 150 bp.

33. The method of any one of claims 30 to 32, wherein the DNA fragment derived from AluYm1 comprises a nucleotide sequence represented substantially by a nucleotide sequence selected from SEQ ID NO: 128-136, including its natural variants.

34. The method of any one of claims 22 to 33, wherein the DNA fragment is amplified from the sample or detected after direct capture.

35. The method of claim 34, wherein the DNA fragment is amplified by PCR, optionally using a forward primer and a reverse primer, wherein the forward primer has a nucleotide sequence selected from SEQ ID NO: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 and 66, and the reverse primer has a nucleotide sequence selected from SEQ ID NO: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63 and 65.

36. The method of claim 35, wherein the DNA fragment is quantified by qPCR, optionally using a TAQMAN or similar real-time PCR system.

37. The method of claim 36, wherein the DNA fragment is amplified by isothermal amplification, and optionally wherein the isothermal amplification is recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), or single primer isothermal amplification (SPIA).

38. The method of claim 37, wherein the isothermal amplification employs a forward primer and an optional reverse primer, the forward primer having a nucleobase sequence selected from SEQ ID NO: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 and 66, and the reverse primer having a nucleobase sequence selected from SEQ ID NO: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63 and 65.

39. The method of claim 37 or 38, wherein the DNA fragment is detected and / or quantified by a lateral flow assay.

40. The method of claim 39, wherein the DNA fragment is amplified using one or more primers conjugated to a detectable marker and a capture portion.

41. The method of any one of claims 22 to 40, wherein the elevated level of the DNA fragment indicates an active inflammatory disease in the subject.

42. The method of claim 41, wherein the inflammatory disease is an autoimmune disease.

43. The method of claim 42, wherein the autoimmune disease is systemic lupus erythematosus (SLE), optionally mild, moderate or severe SLE, and optionally involves lupus nephritis.

44. The method of claim 42, wherein the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, vasculitis, inflammatory bowel disease, and dermatomyositis.

45. The method of claim 41, wherein the inflammatory disease is gout.

46. ​​The method of any one of claims 22 to 45, wherein the subject suffers from or is at risk of thrombotic vascular disease, myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism, and sepsis.

47. The method of any one of claims 22 to 46, wherein the sample is blood, serum, plasma, or urine.

48. The method of claim 47, wherein the sample is plasma.

49. The method of claim 48, wherein the plasma is EDTA plasma.

50. The method of any one of claims 47 to 49, wherein the elevated level is elevated compared to a reference value.

51. The method of claim 50, wherein an EDTA plasma sample is obtained from the subject approximately 5 minutes to 48 hours after administration of the DNA enzyme therapy, wherein the DNA enzyme therapy is optionally DNA enzyme 1-like 3 or a variant thereof.

52. The method of claim 51, wherein an EDTA plasma sample is obtained at least about 15 minutes, or at least about 30 minutes, or at least about 1 hour, or at least about 2 hours, or at least about 3 hours, or at least about 4 hours, or at least about 6 hours, or at least about 8 hours, or at least about 12 hours, or at least about 18 hours, or at least about 24 hours, or at least about 36 hours, or at least about 48 hours after administration of the DNA enzyme therapy.

53. The method of claim 51 or claim 52, wherein the method further comprises comparing the relative abundance of the DNA fragment in the EDTA plasma with a baseline EDTA plasma obtained prior to administration of the DNA enzyme therapy to confirm the therapeutic activity of the DNA enzyme therapy.

54. The method of claim 47, wherein the sample is serum.

55. The method of claim 54, wherein the serum is obtained before and / or after the application of the treatment.

56. The method of claim 55, wherein the treatment comprises DNase treatment, wherein the DNase treatment is optionally DNase 1-like 3 or a variant thereof.

57. The method of any one of claims 54 to 56, wherein the method further comprises comparing the relative abundance of the DNA fragment in the serum with one or more reference values ​​or one or more baseline values.

58. The method of claim 57, wherein the reference value represents the relative abundance of the DNA fragment in the serum of a disease selected from: the active state of the inflammatory disease and the inactive state of the inflammatory disease.

59. The method of any one of claims 22 to 58, wherein the elevated level of the DNA fragment in the subject is tested at a frequency of approximately once daily to approximately once monthly.

Images